esg performance report unite science technology talent get ahead disease together aim positively impact health billion people end successful growing company people thrive building trust operating responsibly integral part report strategy culture approach supports long term growth ceos statement returns shareholders reduces risk helps people thrive delivers sustainable health impact scale approach report progress six focus areas report summarises performance across six environmental access social governance esg focus areas global health health security report line requirements sustainability environment accounting standards board sasb global reporting diversity equity inclusion initiative gri also submit annual un global compact communication progress ungc cop ethical standards product governance addition report report task force climaterelated financial disclosures tcfd pages appendix taskforce naturerelated financial disclosures tnfd materiality assessment pages annual report people disclosures find public positions range issues pricing access human rights clinical trial conduct nature gri sasb index environmental protection supply chain management esg reporting criteria public policy gskcom also publish information independent limited assurance reports gskcom including materiality assessment sustainable development goals engagement patient organisations engagement healthcare professionals trade association memberships charitable partnerships external benchmarking detailed perform key esg ratings ftsegood member ftsegood index since frequently asked investors cdp climate change water security b forests access medicines ranked first access medicines palm oil b forests timber index industry leader antimicrobial sustainalytics low risk rating resistance benchmark msci aa rating sp global corporate sustainability assessment ranked moodys analytics esg overall score first pharmaceuticals industry score sector average november included djsi world iss corporate rating b rating europe indices cautionary statement document may contain forwardlooking statements forwardlooking forwardlooking statements whether result new information statements give groups current expectations forecasts future events future events otherwise investors however consult additional investor identify statements fact relate disclosures group may make documents publishes strictly historical current facts use words 'anticipate ' andor files us securities exchange commission investors 'believe ' 'estimate ' 'expect ' intend ' 'plan ' 'project ' 'target ' 'will ' wherever located take note disclosures accordingly words terms similar meaning connection discussion future assurance given particular expectation met operating financial performance particular include statements investors cautioned place undue reliance forwardlooking relating future actions prospective products product approvals future statements forwardlooking statements subject assumptions inherent performance results current anticipated products sales efforts risks uncertainties many relate factors beyond expenses outcome contingencies legal proceedings dividend groups control precise estimate group cautions investors payments financial results accordance legal number important factors including report could cause actual regulatory obligations including market abuse regulations uk results differ materially expressed implied forward listing rules disclosure guidance transparency rules looking statement financial conduct authority group undertakes obligation update gsk esg performance report march ceos statement pleased report sectorleading esg performance gsk global biopharma company focused prevention significant commitment strengthening health security changing course disease purpose unite science rd projects targeting pathogens deemed critical urgent technology talent get ahead disease together us cdc positively impact health billion people ready phase iii trials lowcarbon version rescue delivering purpose rd based science metered dose inhaler mdi medication ventolin begin immune system new technologies leveraging potential reduce greenhouse gas emissions leadership developing new vaccines specialty medicines use inhaler important scope infectious diseases hiv respiratoryimmunology emissions increased due increased sales oncology product understand responsible business means getting decreased overall water use sites high ahead disease together right way environmental social waterstress regions baseline governance esg impacts embedded strategy end year women held vpandabove roles support longterm growth build trust stakeholders globally ethnically diverse leaders reduce risk deliver positive social impact vpandabove us ethnically diverse leaders vpandabove uk approach centred around six core areas access healthcare global health health security environment set new ai principles shape use ai machine diversity equity inclusion ethical standards product learning transform rd way safe ethical governance responsible continue recognised sectorleading esg report sets progress making area performance ranked st sp global corporate supplements annual report disclosures publish sustainability assessment pharmaceutical industry website maintained leading scores msci iss corporate rating measure esg progress esg performance sustainalytics esg ratings rating introduced one corporate key keep approach esg constant review responding performance indictors drive performance provide greater operating environment evolves includes transparency esg reporting executive leadership team rapidly changing esg regulatory landscape expectations board via corporate responsibility committee companies esg disclosures began necessary review metrics make rating year ensure preparations new sustainability reporting requirements sufficiently challenging ambitious including eus corporate sustainability reporting directive proud continued progress made year csrd committed adopt tnfdaligned disclosures leveraging science technology talent deliver positive based data impact societys urgent challenges look forward delivering strong esg performance esg performance rating track second alongside improving outlook sustained growth consecutive year details found pages decade performance metrics contribute rating overall esg performance rating score independently assured along priority esg data report performance included reaching million people lower income countries emma walmsley access partnerships chief executive officer gavi confirming rollout malaria vaccine mosquirix countries africa progressed global health pipeline assets priority diseases worked partners get ready start phase iii trial promising candidate vaccine mase tuberculosis gsk esg performance report march approach access global health environment dei ethical standards product governance appendix approach environmental social governance esg embedded strategy helps us deliver purpose supports sustainable performance longterm growth global biopharma company purpose unite stakeholder engagement science technology talent get ahead disease together approach esg guided continuous engagement deliver purpose need consider esg impacts stakeholders key stakeholders include patients across everything lab patient thats shareholders customers employees undertake formal esg embedded strategy supports sustainable materiality assessments every twotothree years engage performance longterm growth helps us build trust stakeholders ensure esg focus areas continue generate value stakeholders reduce risk address material issues business operations create positive social impact engage stakeholders covered throughout identified six esg focus areas address report includes engagement people see material business issues matter partnerships ngos membership cross stakeholders focus areas core strategy industry collaborations greatest positive impact societys urgent challenges including set also discuss engagement stakeholders annual un sustainable development goals un sdgs report includes board considers stakeholders decisionmaking see section statement information approach stakeholder access healthcare engagement see policies publications gskcom global health health security gskcom materiality engaging patient organisations engaging environment healthcare professionals investors hub esg diversity equity inclusion dei ethical standards esg governance product governance esg performance monitored regularly board level corporate responsibility committee crc gsk focus areas informed recent materiality leadership team glt crc oversees progress assessment reaffirmed material commitments including performance issues business well aligned six esg focus meeting expectations stakeholders collaborates areas recognise responsible business board committees remuneration committee static requirement began work double materiality audit risk committee ensure esg performance assessment completed means integrated across business continue evolve approach response rapidly changing operating environment strive continuous glt senior management responsible delivery improvement ensure maintain strong esg performance six focus areas report regularly crc progress see pages pages annual report gskcom materiality assessment esgaligned remuneration contribution un sdgs remuneration committee support united nations ' sustainable development goals sdgs crc introduced esg performance measures set vision ending poverty hunger inequality short longterm incentive plans reward delivery key protecting planets natural resources six esg esg measures esg element consists human capital areas identified core strategy management form diversity equity inclusion greatest positive impact aspirations forms annual bonus opportunity societys urgent challenges including set glt climate nature ambitions form sdgs global biopharma company make longterm incentive plan opportunity senior leaders significant contribution sdg good health wellbeing metrics align esg performance rating see publish contribution sdgs website annual report information gskcom contribution sdgs gsk esg performance report march approach access global health environment dei ethical standards product governance appendix approach continued esg performance rating esg performance rating helps us integrate esg assess performance delivery strategy allows us measure verify glt accountable delivering progress esg progress making rating one corporate kpis metrics regularly reviews performance along boards measures progress key metrics aligned crc helps ensure accountability esg performance six focus areas included metrics embedded within business individual metric summarised pages assessed either track metric met continue evolve esg performance rating ensure exceeded track work least metric meets expectations stakeholders executive achieved track metric missed leadership team board via corporate responsibility committee review metrics make rating year calculate overall esg performance rating aggregating ensure sufficiently challenging ambitious performance across metrics single score illustrate year removed two metrics relating access ethical whether track track work track standards added one relating antimicrobial amr rating defined resistance met one metrics relating access developing publishing pricing access principles track metrics track longer required also removed one ethical track work metrics either standards metrics tracks number employees leaving track track work gsk misconduct increases decreases number could track metrics track indicate either higherlower number breaches stronger weaker enforcement processes setting threshold effective measure success upholding standards continue monitor data internally publish externally see three additional metrics provide strong measure commitment ethical standards added metric within global health health security focused amr amr urgent public health threat seen increased stakeholder interest approach updated biodiversity target measured number high risk materials implementing sustainable sourcing roadmaps achieved new target focuses deforestation free sourcing paper palm oil gsk esg performance report march approach access global health environment dei ethical standards product governance appendix approach continued esg performance rating esg performance rating track based performance metrics met exceeded assessment performance annual targets reviewed overall esg performance rating score subject independent limited assurance see esg focus areas six commitments metrics progress access make products progress towards goal reaching reached million people available value billion people lower income countries vaccines antiretrovirals based prices products made million doses products sustainable available lower income countries business implement access strategies increase use medicines vaccines treat protect underserved people global health develop novel progress six global health pipeline assets progressed global health pipeline health products address priority diseases assets address priority diseases security technologies treat including malaria tuberculosis tb prevent priority progress rd projects address progressed active rd projects diseases including pathogens prioritised address pathogens considered critical pandemic threats cdc posing highest level andor urgent threats due drug concern due drug resistance critical resistance urgent threats environment commit net zero climate nature positive operational emissions reduction reduced operational emissions healthier planet scope marketbased emissions ambitious goals set industrialisation lowcarbon ventolin progressed lowcarbon ventolin initiated clinical nonclinical data programme potential reduce available support regulatory submissions greenhouse gas emissions inhaler phase iii trials next generation lowercarbon propellant begin successful regulatory submissions start percentage carbon offset volume carbon offset volume project project pipeline pipeline water average percentage gsk sites average sites key suppliers compliant wastewater active suppliers compliant amr alliance pharmaceutical ingredient limits api wastewater discharge limits percentage sites suppliers primarily compliant amr industry alliance due scope expansion include common antibiotic manufacturing framework api suppliers discharge limits waste materials operational waste material reduction reduction operational waste gsk sites materials sites cope emissions cover emissions direct combustion fuels sites generate heat electricity emissions sales fleet vehicles fugitive losses propellant manufacturing inhalers losses refrigerants used gskowned ancillary equipment emissions onsite waste treatment scope emissions include purchased electricity steam compressed air chilled water percentage mtco offsetting volume project pipeline gsk esg performance report march approach access global health environment dei ethical standards product governance appendix approach continued esg focus areas six commitments metrics progress environment biodiversity percentage paper palm oil paper packaging derived deforestation free certified sources recycled raw materials core palm oil materials certified third parties sustainable sources diversity equity enhance recruitment phase iii trials initiated phase iii trials initiated inclusion diverse patient proactive plans place designed proactive demographic plans populations enrol appropriately diverse trial participants place clinical trials create consistent disease epidemiology inclusive equitable update towards aspirations fair equitable opportunities diverse workplace support diverse aspire women hold least women held vpandabove roles communities vpandabove roles globally end globally compared aspire least ethnically ethnically diverse leaders diverse leaders roles vpand vpandabove us compared us end black increase percentage black african african american leaders vpand american hispanic latinx vpand compared leaders year year hispanic latinx leaders vpandabove compared aspire least ethnically ethnically diverse leaders diverse leaders roles vpand vpandabove uk compared uk end black leaders increase percentage black vpand vpandabove compared leaders year year improve yearonyear spend usbased increased yearonyear spend certified diverseowned suppliers usbased certified diverseowned suppliers ethical promote ethical employees complementary employees standards behaviour across workers complete gsks mandatory complementary workers completed business training gsk 's mandatory training supporting percentage employees believe employees believe employees speak things dont feel speak things dont feel right ' right thing right general industry working benchmark suppliers share standards direct highrisk suppliers direct highrisk suppliers operate achieve gsks minimum ecovadis score achieved minimum ecovadis score responsible way improvement plan place improvement plan place general industry benchmark according research kornferry gsk esg performance report march approach access global health environment dei ethical standards product governance appendix approach continued esg focus areas six commitments metrics progress product commit average number critical major received critical findings governance maintaining robust findings per inspection fdamhra mhra ema regulators quality safety ema regulators processes using percentage inspections inspections critical data new regulators critical findings official findings official action indicated technologies action indicated responsibly number fda warning letters zero fda warning letters total number class iii external product product recalls instances recalls across markets engaged regulators acted quickly prioritise patient safety register disclose human subject registered disclosed human research gsk products specifically register subject research gsk products protocol summaries studies initiated disclose results summaries studies results due culture people purpose unite science technology talent get helping people thrive ahead disease together puts people heart making gsk place people thrive core ahead success together ambition thriving different individual common themes matter everyone firstly belief culture purpose desire live culture contribute committed making gsk place people delivering ambition secondly feeling included able thrive culture ambitious patients opportunities keep growing support accountable impact right thing means feedback space needed succeed finally feeling support people things better faster focusing good positive mental physical financial social matters means setting clear objectives creating wellbeing means gsk place people feel accountability results giving everyone support welcome valued environment including policies space need succeed workplaces ways working enables supports deliver best means everything responsibly integrity care people patients around world count us welcoming developing outstanding people culture embedded everything committed developing outstanding people giving recruitment onboarding training development opportunities grow expect people assessments performance promotion agreed development plan regardless grade role based code sets culture well commitments gsk conversation understand space support need people make deliver ambition succeed continue invest learning development right way people sign initiatives everyone access keep growing code annually personally commit im campus training knowledge sharing platform gskcom see code gskcom digital technology remain core purpose delivery ambitions built people 's skills area global events datacon employees experience immersive sessions see firsthand apply digital data tech tools including generative ai become digitally fluent year employees took part every business unit countries data academy employees access resources online training 've run programmes develop senior leaders ' leadership skills digital age 've also piloted career hub using ai match employees mentors projects potential job opportunities scale gsk esg performance report march approach access global health environment dei ethical standards product governance appendix approach continued enhanced onboarding experience new joiners performance choice introducing monthly live virtual sessions ceo performance choice approach hybrid working senior leaders access senior global leaders officebased roles quarter people allows beginning career us aim provide right balance onsite remote working clear intimate connection gsk patients serve expectations people take accountability spend creating emotional connection purpose strategy enough time together person maintaining flexibility culture complement ongoing local onboarding activities help us continue build sense community connectedness enable development achieve ahead supporting people managers together ambitions data annual employee survey shows people managers play crucial role helping teams broad support approach expectations thrive connecting contributions team makes patient gsk 's broader impact expect people managers recognising rewarding people motivate focus care develop teams sharing success recognising rewarding people deliver training anchored four areas vps equitably progress made invited attend four day inperson event called leading made continues important part culture leaders programme help leaders bring best addition bonus scheme rewards performance across teams foster culture need succeed together company year award people extra also continue invest growing next generation senior ahead together awards delivering exceptional performance leaders support talent succession needs line accountable impact ambitious bespoke development interventions equipping patients right thing identify people leadership skills future missed performance delivering objectives living culture maintaining momentum diversity equity inclusion people experience gsk continuing focus building diverse ensure continue listen people regularly organisation equitable inclusive culture measure experience gsk place work includes everyone feels welcome valued included taking steps annual survey employees featuring questions ensure equal opportunity nondiscrimination engagement confidence inclusivity culture focus areas delivering ambition make leadership teams trust priorities proud engagement levels diverse inclusive support development remained high also continue see high numerous offerings employees including award scores positive upward trends confidence delivery winning leadership development programme accelerating strategy culture focus areas ambitious patients difference also people complete mandatory dei accountability impact right thing well module part annual training year focused measures inclusion expanded analysis survey create inclusive workplace people thrive understand differences employee experience across diverse details dei aspirations see responsible characteristics continue make good progress creating business section error bookmark defined culture workplace people feel sense belonging thrive health wellbeing volunteering measure effectiveness global managers teams health wellbeing benefits support people provide feedback annual one survey different life stages fair inclusive include managers receive anonymised aggregate feedback global minimum standard weeks parental leave primary managers rated highly effective teams secondary carers forms family global minimum standard care family member end life serious health emergencies insured benefits include samesex partners wherever possible mental health training available everyone also enhanced financial wellbeing support employees introducing nudge financial education platform countries helping people manage finances achieve financial goals reignited volunteering across company focused ambition charitable investment themes health people health planet innovators future employees volunteer one two days year taking part teambased handson together days skills based volunteering smaller number people volunteer four days year selected skillsbased volunteering projects gsk esg performance report march approach access global health environment dei ethical standards product governance appendix access aim positively impact health billion people end making vaccines medicines available widely possible responsible pricing strategic access programmes partnerships bn people reached lower income people living hiv vaccine doses supplied countries vaccines access generic product gavi vaccine alliance antiretrovirals containing dolutegravir since commitment esg performance rating metric make products available valuebased prices progress towards goal reaching billion people sustainable business implement access strategies lower income countries products increase use medicines vaccines treat protect underserved people ambition positively impact health billion takes significant time risk investment successfully people end help achieve goal discover develop new medicines vaccines reach billion people lower income countries investment creates products make huge difference medicines vaccines making products patients society generates financial returns required available prices affordable patients fund next generation medicines vaccines getting sustainable business balance right responsible pricing sustainable business fundamental part commitment esg help us find balance follow pricing access principles first published updated october gskcom pricing access principles putting right value innovation aim develop differentiated best firstinclass recognise health inequities including higher income medicines vaccines pursuing areas unmet need countries fund dedicated activities reach underserved deploying cuttingedge science advanced technology populations include disease education helping including genetics artificial intelligence data analytics uninsured underinsured patients navigate health benefits develop effective medicines vaccines speed scale well access programmes provide financial disease precision involve patient development management support us example provided medicines vaccines identify realworld disease challenges prescribed medicines vaccines low income uninsured underinsured medicare part patients set responsible prices line benefits bring gsk viiv healthcares patient assistance patients health systems measured clinical economic programs foundation social outcomes compare offer already available patients generate evidence clinical trials operate robust pricing approvals developing access establish added value provided medicines vaccines plans informed payers also work create stability adjust pricing line socioeconomic status predictability payers business engaging proactively country ensure affordability availability includes using upcoming product launches budget planning tiered pricing vaccines address public health priorities adjusting prices account inflation us low middle income countries based world bank gross combined average net price discounts rebates national income classification viiv healthcare provides nonprofit allowances pharmaceutical vaccines portfolio pricing antiretroviral medicines hiv use public health increased average list price increased programmes lowincome least developed subsaharan compared list industry past five years african countries work within existing payer systems average net price products increased annually recognise need balance health budgets societies average list price rose compared serve list industry million figure includes people reached synflorix rotarix cervarix opv mosquirix vaccines people access generic dolutegravir product voluntary licensing agreements however include people reached albendazole assessment made gsk gsk esg performance report march approach access global health environment dei ethical standards product governance appendix access continued providing access patients lower income countries people living lower income countries continue far lf eliminated countries including disproportionately affected infectious diseases want bangladesh lao pdr announced elimination develop access strategies make real difference disease significant milestones reached million people vaccines antiretrovirals collaborative effort get ahead disease together number lower income countries tablets donating declining year given gradual eradication ntds medicine targeting systematically evaluate pipeline consultation programme benefited million people since global health partners identify products benefit began according data remain committed low lower middleincome countries develop supplying albendazole endemic countries lf eliminated effective focused access plans leastdeveloped countries everywhere lowincome countries file patents medicines enforce historic patents lets companies hiv manufacture supply generic versions medicines countries also support equitable access impactful support development generic versions products gsk products implementing responsible pricing strategies voluntary licences help improve access increasing based countrys ability pay measured gross national manufacturing capacity enabling lower prices eligible income countries aurobindo cipla viatris three generic manufacturers signed sublicences viiv healthcares licence vaccines medicines patent pool develop manufacture supply generic versions cabotegravir longacting hiv reserve lowest vaccine prices gavi similar preexposure prophylaxis cabotegravir la prep organisations partnered gavi since foundation countries subject obtaining regulatory approvals compared supplied one billion vaccine doses oral hiv prevention options cabotegravir la prep date lowest prices lowest income countries complex manufacture viiv supporting companies partnership significantly increased technical knowhow enable generic development supply deliver around million doses cervarix critical access soon possible vaccine lower income countries addressing cervical cancer viiv also works global health agencies nongovernmental supplied around million doses pneumococcal organisations governments community partners plan vaccine synflorix seven gavieligible countries lowest support introduction viivmanufactured cabotegravir price vaccine rotavirus rotarix reaches children la prep national programmes late first orders across gavieligible countries four former gavi countries cabotegravir la prep delivered global partner offered vaccines civil society organisations serving programmatic use low middleincome countries refugees working emergency situations humanitarian mechanism since also longstanding viiv healthcare also voluntary licensing agreements supplier oral polio vaccines unicef generic manufacturers produce sell lowcost single supplied around million doses help eradicate polio fixeddose combination products containing hiv medicine dolutegravir adults agreements cover low neglected tropical diseases middleincome countries one direct licence others working partners since tackle via medicines patent pool similar agreements neglected tropical diseases ntds including lymphatic filariasis generic manufacturers children covering countries lf debilitating disease caused parasite transmitted well separate agreements enable greater access humans mosquitoes reduce morbidity intestinal dolutegravir certain upper middleincome countries worms echinococcosis donated million includes generic dolutegravir dispersible tablet mg formulations albendazole tablets help end ntds taking total children living hiv first received fda tentative donated billion approval us pepfar scheme three years ago available countries access facilitated viivs publicprivate partnership clinton health access initiative unitaid two generic manufacturers sublicences medicines patent pool total around million people living hiv across countries access generic product containing dolutegravir end people living hiv antiretrovirals genericaccessible low middle income countries gsk esg performance report march approach access global health environment dei ethical standards product governance appendix access continued malaria significantly increase supply vaccine medium term transferring technology knowhow bharat biotech date two million children ghana kenya malawi india sole supplier vaccine reached least one dose mosquirix rtss continue make good progress product transfer ase whocoordinated malaria vaccine implementation programme developed gsk partners results landmark study london school mosquirix significant scientific breakthrough worlds hygiene tropical medicine showed combining mosquirix first malaria vaccine first vaccine human antimalarial drugs areas africa seasonal malaria parasite reduced malaria cases deaths young children period five years findings confirm potential july gavi announced nine african countries seasonal vaccination provide high level protection allocated doses mosquirix early early first five years life protection much needed cameroon burkina faso became first countries introduce vaccine routine immunisation programmes committed supply million doses gavieligible countries plan produce million doses annually strengthening healthcare systems collaborate partners strengthen healthcare systems september announced renewed key addressing systemic issues reduce access partnership save children another five years date healthcare vaccines treatments perpetuate partnership provided million children health inequalities lower income countries work people essential healthcare trained equipped underserved communities make sure take health workers remote marginalised communities lead decisions affect health advocated incorporation stronger policies help support emergency preparedness response protect childrens health country global level work partnership organisations active within building learnings last decade focusing local communities look catalyse additional resources partnership reducing number zero dose children increase impact gsk viiv healthcare joined forces never received vaccine ethiopia global fund pledge million three years nigeria represent third zerodosed create gender equality fund support community children africa based led organisations working deliver lasting last year launched two new programmes part changes health policies programmes transform gender longstanding partnership amref health africa one focuses norms eliminate discrimination improve health outcomes malaria kenya zambia second address focus tb hiv malaria gates foundation antimicrobial resistance amr across region work committed match donation support global regional office africa african cdc identify fund 's work assess national amr plans support implementation mobilised connected communitybased organisations gsk viiv healthcare committed responding vital part health systems enabling access delivery humanitarian crises possible date gsk donated services especially hardtoreach populations positive action million number partners including red viiv healthcare 's community grantgiving programme works cross save children global fund directly responding directly communities affected hiv humanitarian crisis ukraine neighbouring countries viiv healthcare mission ensuring person living hiv viiv healthcare continued donate antiretroviral left behind positive action invested million medicines national hiv aids programmes poland reaching approximately people providing grants support people living hiv affected across countries conflict ukraine date company donated packs positive action also launched ukraine emergency response fund positive action made available partners based ukraine neighbouring countries protect health people living affected hiv region gsk esg performance report march approach access global health environment dei ethical standards product governance appendix access continued community investment cash product inkind time management costs total community investment value gsk medicine vaccines provided us patient assistance programs foundation us pricing year change list net price change combined average net price pharmaceutical vaccines portfolio us since previous year change average list price us since previous year year list net price compound annual growth rate change net price discounts rebates allowances products us past years change average list price us past years product reach doses supplied lower income countries doses synflorix vaccines supplied gavi pr doses rotarix vaccines supplied gavi pr doses cervarix vaccines supplied gavi pr doses opv vaccines supplied unicef pr doses mosquirix rtssas e vaccines supplied pr albendazole tablets donated help eliminate lymphatic filariasis pr albendazole tablets donated help treat intestinal worms pr total doses supplied pr product reach people reached lower income countries people access generic dolutegravir product voluntary licensing agreements ' estimated children reached synflorix gavi ' estimated children reached rotarix gavi ' estimated girls reached cervarix gavi ' estimated people reached opv unicef ' estimated people reached mosquirix rtssas e ' total people reached ' pr metric contributes esg performance rating metrics data independently assured product donations valued global average cost goods reported yearend results product donation included within total community investment figures reported calculated across gsk viiv healthcare products chronic ongoing treatment cumulative number people access dolutegravir rather annual data reported figure estimated based sales generic dolutegravirbased products voluntary licensing agreements updated methodology include sales generic dolutegravirbased products n also held million doses opv vaccine readytoship stockpile case epidemic making total million doses products available lower income countries contributed access performance rating metric independently assured gsk esg performance report march approach access global health environment dei ethical standards product governance appendix access continued people reached healthcare access programmes people accessing healthcare service worker educational session work save children ' people accessing healthcare worker service facility result bill melinda gates ceo roundtable programme ' people reached viiv healthcares positive action children fund grants ' people reached viiv healthcares positive action strategy grants ' people reached us patient assistance programs ' pr metric contributes esg performance rating metrics data independently assured data restated due data subsequently becoming available bill melinda gates ceo roundtable programme concluded therefore amount reported reach data collected grantees every six months previous six months activity month cycle data restated gsk esg performance report march approach access global health environment dei ethical standards product governance appendix global health health security want help address biggest health challenges faced people around world global health pipeline assets rd projects relevant rd projects targeting pathogens address priority antimicrobial resistance deemed critical urgent diseases progressed pipeline us cdc commitment esg performance rating metrics develop novel products technologies treat progress six global health pipeline assets address priority prevent priority diseases including pandemic threats diseases progress eight active rd projects address pathogens prioritised cdc posing highest level concern due drug resistance critical andor urgent threats people live continues influence chances enjoying viiv healthcare announced investment healthy life people living lower income countries billion years accelerate global health rd disproportionately affected infectious diseases among end invested progressed biggest drivers morbidity mortality tuberculosis tb global health pipeline assets address priority diseases malaria antimicrobial resistance amr hiv neglected including climateaggravated diseases tropical diseases disproportionately affecting lower income countries gsk proud heritage leader global health strong resilient healthcare systems critical enabling unique important role play improving health patients access right treatments vaccines working around world using science technology talent longterm partners help strengthen healthcare systems lower partnerships deliver health impact scale prevent income countries driven local needs work increase prepare respond future health security challenges underserved peoples access medicines vaccines described access including viiv healthcare working potential vaccines medicines targeting high burden infectious diseases putting unique rd scientific expertise work address worlds biggest health challenges global health rd promising avenues tb prevention treatment also developing portfolio shorter safer simpler tb treatments combination medicines could gsk committed tackling tb one worlds deadliest transform tb landscape part new regimens infectious diseases developed promising candidate drugsensitive drugresistant tb patients advancing vaccine mase proof concept phase iib building four novel medicines clinical development nine rd longstanding successful history working external consortia partnerships combine expertise share risk partners partnered bill melinda gates leverage resources accelerate innovation medical research institute mri development gates mri well positioned lead large complex phase iii study gsk lead industry partner two large eufunded innovative required june wellcome bill melinda gates medicine initiative projects eratb unitetb together foundation announced funding million phase iii aim progress numerous assets preclinical phase trials trials successful mase could first new iiiready compounds vaccine help prevent pulmonary tb century b udget phasing linear across year period gsk esg performance report march approach access global health environment dei ethical standards product governance appendix global health health security continued breakthroughs malaria research treatment also used data semifield studies conducted institut de recherche en sciences de la sant irss contained latest data shows estimated million mosquitosphere facility burkina faso suggests malaria cases deaths caused malaria laboratory findings could successfully translated according africa field malaria control continue pursue ground threequarters children five date together breaking research engaging global health institutions partners weve brought two products prevention partners identify effective sustainable treatment malaria market worlds first vaccine approach development mobilisation successful malaria see access singledose radical cure p vivax malaria reported getting ahead malaria supporting innovation capacity particularly challenging due growing resistance existing drugs insecticides climate change enables spread capability building disease investing develop next generation africa open lab initiative launched transformative tools support earlycareer scientists based subsaharan africa focus infectious diseases disproportionately affect august announced gsk scientists discovered subsaharan populations malaria tb amr strain naturally occurring bacterium could potentially agreed grants ten researchers six countries subsaharan help eradicate disease tres cantos tc strain africa announced call proposals november delftia tsuruhatensis bacterium named gsk rd also working african academic institutions provide facility discovered significantly reduces load grantees supplemental training areas including p falciparum malaria parasites mosquitoes could epidemiology statistics clinical research potentially inhibit transmission parasite humans tc shown effective multiple types anopheles mosquito multiple types malaria parasite ground breaking research conducted collaboration johns hopkins malaria research institute johns hopkins bloomberg school public health strengthening health security many factors jeopardise health security december first patient dosed pivotpo new emerging infectious diseases rise amr pivotal phase iii trial tebipenem approved tebipenem hbr climate change nature loss also change disease address unmet medical need novel oral antibiotic patterns using scientific knowhow collaborating alternative intravenous hospital therapy drugresistant others help world better prepare future health cutis march announced exclusive licence challenges agreement scynexis brexafemme ibrexafungerp tablets firstinclass antifungal treatment vulvovaginal getting ahead amr innovation candidiasis vvc reduction incidence recurrent appropriate use vvc founded gsks science technology primary vaccines remain important pathway getting ahead contribution strengthening health security resistant infections year us fda granted innovation prevent mitigate infectious disease fast track designation investigational vaccine includes investing innovation get ahead infections gonorrhoea second prevalent bacterial new antimicrobials vaccines urgently needed sexually transmitted infection worldwide estimated rd projects across medicines vaccines million new cases globally year recognised urgent relevant amr ranging early latestage unmet medical need due growing global incidence development rd projects targeting pathogens deemed reduced efficacy available treatments drugresistant strains critical urgent us cdc increasing include gepotidacin could first novel oral see annual report rd antibiotic treatment uncomplicated urinary tract infections pipeline uutis years positive phase iii data eagle eagle phase iii trials presented european congress clinical microbiology infectious diseases copenhagen april partnership spero therapeutics inc exclusive licence agreement tebipenem hbr latestage oral carbapenem antibiotic potential treat complicated urinary tract infections cutis gsk esg performance report march approach access global health environment dei ethical standards product governance appendix global health health security continued progressing vaccines enteric diseases support responsible manufacturing antibiotics work amr industry alliance set global limits wastewater reduce burden amr antibiotic discharges factories see environment amr major threat health globally particularly work strengthen responsible manufacturing antibiotics prevalent low resource settings deepening existing health highlighted example good practice report inequities risking efficacy current medicines fight issue access medicine foundations amr diseases continue progress candidate vaccines benchmark several enteric diseases contribute burden amr including invasive nontyphoidal salmonella klebsiella shigella also continued support dialogue around rebuild typhoid paratyphoid fever ecosystem antimicrobial innovation participating discussions topic brussels washington london announced partnering limmatech biologics development one candidate vaccine partnering pandemic preparedness shigellosis continue develop another countries continued manage repercussions candidate vaccine disease uses vaccine covid pandemic health security remained high global platform technology gmma currently vaccines agenda united nations held highlevel meetings help prevent shigellosis disease causes deaths pandemic preparedness response universal health year coverage white house established pandemic preparedness response office ensuring appropriate use antibiotics ensuring appropriate access infectious disease interventions help preempt respond next health security key getting ahead health security threats continue emergency working governments maintain strong focus appropriate use antibiotics stakeholders strengthen global preparedness means enabling access committed exploring drawing learned covid previous lower income focused indications antimicrobials outbreaks championing innovation promoting sustainable vaccines development help maximise health impact approaches biopharmaceutical sector public health continue train healthcare professionals around world continue monitor potential threat pandemic using prescribing antibiotics appropriately influenza emerging infectious diseases pandemic importance surveillance studies well maintaining potential engage pandemic preparedness dialogue longrunning multinational survey antibiotic resistance g skcom position antimicrobial resistance programme developing new resistance surveillance programmes support antimicrobial assets latestage development january infection index launched india designed provide convenient access information data support physicians appropriate antibiotic decisionmaking global health pipeline assets priority diseases number assets progressed global health pipeline address priority diseases pr number active rd projects address pathogens prioritised cdc posing pr highest level concern due drug resistance critical andor urgent threats pr metric contributes esg performance rating metrics data independently assured gsk esg performance report march approach access global health environment dei ethical standards product governance appendix environment climate change nature loss urgent threat human health well risk business resilience get ahead disease help ensure longterm business success need take action climate nature reduction operational gsk sites completed gsk manufacturing sites carbon emissions scope baseline biodiversity within amr alliance assessments wastewater api quality limits commitment commit net zero nature positive healthier planet freshwater ambitious goals set average percentage gsk sites suppliers compliant wastewater active pharmaceutical ingredient esg performance rating metrics api limits percentage sites suppliers climate compliant amr industry alliance common antibiotic operational emissions reduction scope market manufacturing framework discharge limits based emissions land industrialisation lowcarbon ventolin initiated clinical percentage paper palm oil deforestation free nonclinical data available support regulatory submissions waste materials percentage carbon offset volume project pipeline operational waste material reduction sites climate change nature loss creating new health threats also working address impacts climate change changing spread burden disease health investing rd medicines vaccines vulnerable communities disproportionately affected puts climate aggravated infectious diseases disproportionately increasing pressure healthcare systems already account impact vulnerable communities working nearly global emissions partners increase resilience healthcare systems climate change information see global health thats set ambitious environmental goals aim address impacts across entire collaboration across entire value chain patients value chain drug discovery disposal products suppliers regulators peers vital achieving goals help make gsk resilient protect supply chains help also collaborate internally ensure embed climate us adapt ahead anticipated regulation change provide nature considerations throughout business potential growth opportunities demand increases medicines vaccines lower environmental impact climate clear pathway net zero impact climate targets ambitious goals absolute reduction greenhouse gas emissions value chain carbon footprint made baseline across scopes investment nature based solutions remaining footprint scope emissions operations imported renewable electricity scope emissions supply chain renewable electricity imported generated scope emissions logistics scope scope emissions people using products net zero greenhouse gas emissions across full value chain mostly metereddose inhalers absolute reduction emissions baseline scope emissions disposal products across scopes residual emissions neutralised hese metrics related esg performance rating outlined pages also measure report performance environmental sustainability targets publish gskcom based data target boundary includes biogenic landrelated emissions removals bioenergy feedstocks gsk esg performance report march approach access global health environment dei ethical standards product governance appendix environment continued science based targets initiative sbti approved sustainable procurement programme requires suppliers gsks net zero target line corporate netzero take action climate nature time standard worlds framework corporate net zero target actively support suppliers adopt new environmental setting line climate science sustainability measures particular focus top suppliers climate nature impact g skcom net zero pathway started include contract clauses carbon reductions managing operational footprint priority suppliers top suppliers reduced scope carbon emissions carbon emissions submitted science based targets compared compared validation eight targets approved baseline primarily due energy efficiency measures completed deepdives two key suppliers increasing amount renewable electricity use identify opportunities reduce energy water usage example nashik site india reduced emissions switch renewable energy sources since moving renewable biomass heat also engaging broadly across supply chain renewable electricity may part supplier forum attended member initiative committed reach suppliers held three sustainability roundtables focused imported electricity renewable sources addressing common challenges potential solutions electricity generate import launched sustainability foundations programme january renewable sources reached imported gsk procurement employees attending three renewable electricity increase hours training focused climate nature participants reported increase confidence competence signed power purchase agreement source renewable explaining ambition suppliers ensuring electricity cover electricity demand sites environmental goals aligned europe mid two additional wind turbines new solar farm manufacturing facility irvine scotland began supply chain emissions shared challenge sector generating renewable energy working collaboration across industry programmes like activate energize sustainable markets seek follow leading practice laboratory sustainability initiative smi health systems task force find solutions seven laboratories united states canada uk achieved green lab certification considered date top suppliers carbon emissions gold standard laboratory sustainability best practices registered join activate programme focused reducing around world covering community engagement energy water emissions production active pharmaceutical waste resource management three received ingredients highest level certification ten laboratories certified july ceo signed open letter alongside healthcare across network ten assessment process leaders smi health systems task force calling member ev committed transition suppliers signup joint minimum climate fleet electric hybrid vehicles install chargers sustainability targets set task force sites pluginhybrid fully electric vehicles made december green lab launched converge collaborative sales fleet total fleet supply chain initiative encourage suppliers reduce chargers major sites increased number environmental impact labs value chain gsk one charging points nearly founding sponsors initiative addressing scope emissions emissions use products overall scope emissions lower baseline use medicines vaccines makes total year although increase latest footprint propellant used metereddose available data compared primarily driven inhalers asthma chronic obstructive pulmonary disease higher sales metered dose inhaler products set copd steps taking reduce emissions associated gsks rescue metered dose inhaler mdi medication ventolin metered dose inhalers although overall scope emissions salbutamol essential medicine prescribed approximately increased period reduced million people respiratory conditions worldwide patient upstream scope emissions suppliers see use inhaler due current propellant accounts half carbon footprint investing supply chain emissions lowcarbon programme potential reduce greenhouse goods services buy make medicines gas emissions inhaler transitioning next vaccines additional upstream emissions account generation lowercarbon propellant phase iii trials begin approximately total carbon emissions footprint successful regulatory submissions start supply chain emissions fell supplement existing low carbon dry powder inhalers climaterelated financial disclosures see pages annual report disclosure climate risk resilience line task force climate related financial disclosures tcfd framework gsk esg performance report march approach access global health environment dei ethical standards product governance appendix environment continued nature shared detail plan contributing achieved overall water reduction target naturepositive world line goal global reduced overall water use operations additional biodiversity framework halt reverse biodiversity loss compared sites high waterstress sets approach action nature four regions decrease overall water use focus areas freshwater land oceans atmosphere sites high waterstress regions baseline including biodiversity living species across areas implemented water efficiency reuse systems aim deliver contribution three ways avoiding number sites including pakistan increasing reducing impact nature protecting restoring nature recycled water capacity wavre site belgium pilot helping accelerate collaborative action approach wastewater treatment station installed enable reuse aligned work taskforce naturerelated wastewater reduce water consumption financial disclosures tnfd science based target network sbtn sites key suppliers located waterstressed areas developing catchmentlevel water replenishment restoration overuse natural resources generation waste regeneration projects deliver water neutrality target pollution key drivers nature loss also set underlying targets waste materials partnered local ngo watershed organisation trust wotr nashik india water replenishment project may selected part first group designed improve ecosystem conditions enhance climate companies participate initial target validation process resilience local agriculture help local villages manage sbtn set validated sciencebased targets nature water resources improve health livelihoods starting targets freshwater land followed targets oceans biodiversity targets focus locations also founding partner women water across value chain nature particularly pressure collaborative india launched october working water resilience coalition initiative un tnfd published final framework september outcome global compact pacific institute programme brings pilot framework others already testing together companies different sectors leverage womens announced commitment adopting tnfdaligned leadership improve access clean water sanitation disclosures based data already started ultimately supporting health local communities implement final recommendations disclosure annual report committed ensuring discharges manufacturing apis including antibiotics adversely affect gskcom plan contributing nature positive world people environment sites key suppliers compliant amr alliance api wastewater discharge freshwater limits driven us expanding continue work towards existing water targets set scope include api suppliers led decrease part sbtn pilot currently working percentage key suppliers confirmed within implement guidance validate freshwater targets wastewater api discharge limits engaging targets additional suppliers assess alignment discharge limits support improvements necessary gsk sites achieve good water stewardship sites within amr alliance wastewater api quality limits reduce overall water use operations support responsible manufacturing antibiotics work water neutral operations key suppliers amr industry alliance set global limits wastewater waterstressed regions antibiotic discharges factories work strengthen achieve zero impact active api levels sites key responsible manufacturing antibiotics highlighted suppliers example good practice report issue depend water production vaccines access medicine foundations amr benchmark medicines primary impact water availability manufacturing sites located areas waterstress land sites good water stewards line alliance continue deliver existing land targets set water stewardships definition started alliance additionally piloting sbtn guidance setting land water stewardship standards certification process five targets waterstressed sites algeria india pakistan site teams targets passed training standard working implement positive impact biodiversity sites agricultural forestryderived materials sustainably sourced deforestation free n previous esg performance reports nature targets grouped water waste materials biodiversity published plan contributing nature positive world september updated target categories align four areas nature defined tnfd sbtn underlying targets waste materials targets remain predicted noeffect level gskowned sites gsk esg performance report march approach access global health environment dei ethical standards product governance appendix environment continued land degradation due poor land management land example use horseshoe crab blood important conversion range negative health impacts substance required regulators used primary dependency land natural materials pharmaceutical biomedical quality control processes source derive agricultural commodities ensure quality safety medicines vaccines devices production drive deforestation landuse change continue make progress volume reductions completed baseline assessments six sites advancing pilot across five sites test use non meaning assessed sites using natural animal alternatives time engaging england biodiversity net positive methodology parallel regulators support wider uptake alternatives plans place improve biodiversity nine sites horseshoe crab blood fully replaced working increase six suppliers improve sustainability new sustainable may set ambitious new sustainable sourcing sourcing standards discussed include specific marine standards suppliers provide us materials sustainable sourcing standard outlines requirements highly dependent nature like lactose gelatine soy suppliers marinederived materials must adhere standards developed collaboration thirdparty experts conducted physical site audits key suppliers understand aim support suppliers assess improve verify adoption standard approach addressing range nature impacts associated climate social impacts including landuse atmosphere water stewardship biodiversity air quality closely linked climate change many roadmaps place aim achieve drivers air pollution burning fossil fuels also sources sustainablysourced paper packaging palm oil greenhouse gas emissions air pollution significant risk paper packaging derived certified human health particularly patients respiratory conditions sources recycled raw materials core palm like asthma copd oil materials certified third parties approach air pollution includes reducing pollutants linked sustainable sources improve palm oil sourcing burning fossil fuels addressed via sbtialigned practices joined action sustainable derivatives climate targets set well looking industryled collaboration tackle environmental social broadly air pollution footprint supply chain issues around palm oil derivatives help accelerate collective action air pollution working suppliers key part goal reduce members alliance clean air clean air fund impact nature appropriate also look caf world economic forum aims drive opportunities reduce avoid use natural materials corporate action clean air accelerate climate action example process efficiencies synthetic create healthy communities around world alternatives example extract soapbark tree done initial assessment establish air pollution essential ingredient vaccine adjuvants used footprint operations supply chain highlighted enhance immune response vaccines working opportunities reductions emissions linked onsite process improvement deliver significant yield increase electricity generation use solid fuels car use move reducing nature impact improving supply resilience electric fleet well indicating opportunities value chain gskcom approach sourcing materials highly sourcing plastic glass products creating dependent nature reduction plans around key areas aligned pathway zero aim positive impact air oceans quality continue deliver existing ocean target set conducting additional air quality assessment working apply relevant sciencebased methodology stockholm environment institute sei university oceans becomes available york broadening suite air pollutants taken target consideration understand impact across value chain marinederived materials sustainably sourced connection human health degradation worlds oceans caused factors climate change marine pollution overfishing poses risks human health business resilience impacts dependencies oceans come primarily marinederived materials critical part manufacturing vaccines medicines including reduction routine hazardous nonhazardous waste regulatory obligations allow excluding plastics critical product discovery development health safety gsk esg performance report march approach access global health environment dei ethical standards product governance appendix environment continued waste materials gsk sites manufacturing pvcfree secondary tertiary packaging also implemented first pilot overuse natural resources generation waste electronic patient information replace paper leaflets pollution key drivers climate change nature loss singapore targets solvent reduction strategy rolled across sites approach product stewardship means consider key suppliers includes designing solvents using lower aim address impacts nature climate every stage impact solvents improving solvent recovery rates product life cycle discovery design sourcing manufacturing product use disposal set waste target help accelerate adoption approach reduced operational waste compared environmental impact reduction products total since increased amount packaging materials recovered circular routes also set targets reduce operational supply maintained zero operational waste landfill chain waste continue build longstanding operational waste management programme identify opportunities find zero operational waste including eliminating singleuse beneficial uses waste plastics example wastewater treatment facility jurong waste reduction supply chain site marburg germany reducing amount product stewardship waste incinerated approach product stewardship across new supply chain working waste footprint existing products built scientific method environmental assessment help supplier engagement waste reduction footprinting called life cycle assessment lca worked external specialists codevelop internal product carbon investing nature footprinting tool building lca process covers investing nature protection restoration key part climate nature inform scientists engineers ambition commitment achieve net zero nature positive develop new products also use publicly available tools healthier planet aim making investments need share information outside gsk nature across value chain also prioritising nature embed sustainability design future products investments carbon credits committed securing developed set ecodesign principles help guide part pathway net zero emissions decisionmaking approach partner expert developers investors actively working part consortium eight global ngos invest earlystage nature projects long term pharmaceutical come together via pharmaceutical gsk investor climate asset managements nature based environment group peg support smi co carbon fund aims invest landscape scale develop shared way measuring reporting environmental grassland agriculture forestry wetlands coastal carbon product data projects developing economies provide longlasting verified since completed lca analysis products positive impact scale climate biodiversity local enabled us identify need improve communities longterm investment next years manufacturing design assess potential savings design aims secure approximately quarter credits changes provide productlevel information key need meet commitment invest naturebased customers specific products solutions footprint help ensure human health key outcome worlds drive protect restore nature september published opensource toolkit partnership pollination developed input key nature health experts organisations circular bioeconomy alliance nature climate solutions alliance london school hygiene tropical medicine toolkit aims support companies investors developers incorporate health considerations design naturebased projects seeking test toolkit nature investments make methodology changed include waste materials leaving sites regulatory obligations allow excluding plastics critical product discovery development health safety gsk esg performance report march approach access global health environment dei ethical standards product governance appendix environment continued energy natural gas purchased gwh electricity used gwh purchased renewable electricity gwh purchased nonrenewable electricity gwh onsite renewably generated electricity gwh exported electricity gwh coal gwh fossil fuels gwh renewable heat gwh purchased heating cooling gwh total energy operations gwh renewable electricity carbon scope emissions onsite fuel use thousands tonnes coe sales force vehicles thousands tonnes coe propellant emissions manufacture inhalers thousands tonnes coe onsite waste wastewater treatment thousands tonnes coe refrigerant gas losses thousands tonnes coe total scope emissions thousands tonnes coe electricity marketbased emissions thousands tonnes coe purchased heating cooling thousands tonnes coe total scope marketbased emissions thousands tonnes coe total scope locationbased emissions thousands tonnes coe total scope marketbased emissions thousands tonnes coe pr fermentationbiogenic releases thousands tonnes coe carbon scope emissions purchased goods services thousands tonnes coe capital goods thousands tonnes coe fuel energyrelated activities thousands tonnes coe transportation distribution upstream thousands tonnes coe waste generated operations thousands tonnes coe business travel thousands tonnes coe employee commuting thousands tonnes coe leased assets upstream thousands tonnes coe transportation distribution downstream thousands tonnes coe processing sold products thousands tonnes coe pr metric contributes esg performance rating metrics data independently assured ther propellant emissions data collected internal systems accurate picture scope emissions later year gsk esg performance report march approach access global health environment dei ethical standards product governance appendix environment continued use sold products thousands tonnes coe emissions use propellantbased inhalers patients thousands tonnes coe end life thousands tonnes coe leased assets downstream thousands tonnes coe franchises thousands tonnes coe investments thousands tonnes coe total scope emissions thousands tonnes coe ozonedepleting substances odp inventory cfc hcfc equipment kg cfce odp calculated releases cfce kg cfce water use municipal million ground water million tankers million total water use million recycled sources million water use high water risk sites million water discharge wastewater municipal sewers million wastewater surface water million wastewater land million wastewater million total wastewater discharged million gsk sites supplier locations used gsk compliant amr alliance pr wastewater api limits pr metric contributes esg performance rating metrics data independently assured gsk esg performance report march approach access global health environment dei ethical standards product governance appendix environment continued waste materials total waste recovered via circular route thousand tonnes total waste disposed via noncircular route thousand tonnes total waste materials generated thousand tonnes pr circular waste total hazardous waste recovered via circular route thousand tonnes total hazardous waste disposed via noncircular route thousand tonnes total hazardous waste thousand tonnes total nonhazardous waste recovered via circular route thousand tonnes total nonhazardous waste disposed via noncircular route thousand tonnes total nonhazardous waste thousand tonnes total hazardous waste incinerated thousand tonnes total nonhazardous waste incinerated thousand tonnes total waste incinerated thousand tonnes total hazardous waste landfill thousand tonnes total nonhazardous waste landfill thousand tonnes total waste landfill thousand tonnes sustainable sourcing percentage paper deforestation free pr percentage palm oil deforestation free pr compliance remediation number gsk internal audits number gsk sites independently certified iso environmental fines 's remediation spend pr metric contributes esg performance rating metrics data independently assured ethodology changed include waste materials leaving sites restated waste materials data reflect please see environmental data table detail gsk esg performance report march approach access global health environment dei ethical standards product governance appendix diversity equity inclusion want ensure people thrive foster diversity clinical trials support diverse communities becoming inclusive business central purpose phase iii trials included vpandabove roles held ethnically diverse leaders demographic plan women globally vpandabove uk commitment create diverse equitable inclusive workplace enhance update towards aspirations fair equitable recruitment diverse patient populations clinical trials opportunities support diverse communities aspire women hold least vpandabove roles globally end esg performance rating metrics aspire least ethnically diverse leaders phase iii trials initiated proactive roles vpandabove us end plans place designed enrol appropriately diverse trial increase percentage black african american participants consistent disease epidemiology hispanic latinx vpandabove leaders year year improve yearonyear spend usbased certified aspire least ethnically diverse leaders diverseowned suppliers roles vpandabove uk end increase percentage black vpandabove leaders year year becoming diverse inclusive equitable business clinical trial diversity help attract retain outstanding talent bringing greater diseases medicines affect people differently depending opportunity create better health outcomes patients ethnicity sex race age means important want better health outcomes clinical trials need ensure patients people enrolled clinical trials reflect populations affected diseases aiming represent realworld patientpeople population use address backed latest scientific research working medicines vaccines represent affected make sure recruit participants clinical trials line disease study epidemiology diseases question continue make progress advancing clinical trial diversity inclusive business make peoples addition ensuring phase iii trials diversity potential increase positive impact culture allow plans place enrol groups affected disease people thrive want leadership reflect gsk studied based disease epidemiology also people people reflect communities work hire challenging actively monitor patient recruitment diversity brings better insights betterquality decision real time ensure reach diversity goals met making help us perform better understand diverse objective phase iii interventional trials initiated patients want truly inclusive working environment proactive diversity plans employees diverse perspectives february published study years gsk characteristics valued thrive perform best viiv healthcare us clinical trial diversity data showed help us get ahead disease together enrolling participants clinical trials based realworld disease build diverse workforce need diverse pool job epidemiology data rather census data would ensure applicants working improve access stem trials reflect populations affected different diseases education among underrepresented communities efforts example us census bureau data indicates extend community programmes secondary education total us population blackafrican american however working universities mentoring young people epidemiology shows us hiv patients recently diagnosed beginning careers us blackafrican american using epidemiologic data guide enrolment clinical trials allowing us set representative trial enrolment goals gsk esg performance report march approach access global health environment dei ethical standards product governance appendix diversity equity inclusion continued publicly sharing research hope advance uk end ethnically diverse discussion around clinical trial diversity improve leaders vpandabove compared pharmaceutical sector approaches issue clinical trial black leaders vp level compared diversity us end ethnically diverse leaders vpandabove compared supporting diversity supply chains black african american leaders vpandabove engaging mentoring small diverseowned compared hispanic latinx businesses supply chain help identify leaders vpandabove compared potential areas growth increased investments working ensure representative pool select suppliers marketing sales technology job applicants hire us continue addition significantly increased partnerships external engage historically black colleges universities advocacy groups deepened relationships key existing hispanic serving institutions employee alumni diverse suppliers onboarded new diverse suppliers encourage applications graduate experienced hire year expanded successful us supplier diversity positions target recruitment campaigns reach programme uk programme provides opportunities represented groups underrepresented groups including women ethnic minorities highly talented diverse team essential help us get members lgbtq community people disabilities ahead disease together fair equitable pay practices military veterans well small businesses high help ensure create environment people feel unemployment lowincome communities welcome valued included supported thrive conduct countrybased reviews ensure markets supporting inclusive culture clear guidance tools support ensure pay equity code requires people commit inclusive unexplained differences detected address aware impact others annual mandatory training compensation processes focus pay equity creating inclusive workplace sets standards building diverse organisation helps us deliver strong uk expect pay gap results gskcom code gender pay gap permanent ukbased gsk employees mean compared national average building diverse organisation second time reporting uk ethnicity pay gap comparing average pay white fundamentally committed equal employment ethnically diverse employees uk ethnicity pay gap opportunity nondiscrimination employees permanent ukbased gsk employees mean want leadership reflect gsk people people compared reflect communities work hire set leadership aspirations race ethnicity senior addition within uk ethnicity pay gap report positions us uk gender aspirations senior also sharing pay gaps comparing average pay positions globally support ensure recruitment white employees ethnic groupings black selection processes fair equitable mixed asian reference uk governments recently published guidance provide vacancies senior grades expect diverse shortlists granular view interview panels gender ethnicity working recruitment agencies internal employee resource gskcom gender pay gap report ethnicity pay gap report groups specialist organisations drive progress hiring managers required complete inclusive interview training inclusive accessible place work start selection processes workplaces must inclusive accessible end women held vpandabove roles culture empathy acceptance embrace globally compared women made others differences identities employee resource groups employees management roles ergs employeeled communities collaborate business achieving strategic priorities line countries meet criteria data confidentiality global inclusion diversity strategy alongside councils anonymity disclose race ethnicity people focused single aspects diversity like race gender year level set aspirations leadership representation also created new forum intersectionality inclusion reflect available talent employee population council various ergs provide cross external communities currently uk us meet dimensional input priority global initiatives affect criteria employees scale gsk esg performance report march approach access global health environment dei ethical standards product governance appendix diversity equity inclusion continued year undertook uks business disability forums year relaunched mental health matters training disability smart assessment showed made clear available globally designed help people spot signs improvements last three years making adjustments poor mental health know start conversation people disabilities recruitment retention built others signpost resources support everyones wellbeing environment technology developing new threeyear plan improve meet needs supporting diverse innovators future people disabilities investing stem education make equitable taking needs people account using support inspire next generation diverse talented inclusive design standards new retrofitted innovators facilities including new global headquarters london gsk science summer initiative offers free handson standards aim ensure workplaces welcoming stem learning community settings students us people groups traditionally underrepresented stem careers also partnered purplespace sponsor series underresourced communities reached confident conversation guides available guides children across us since launch resource people disabilities health conditions committed million years support help build confidence personal resilience also useful number women black latinx students philadelphia colleagues managers leaders learn entering stem careers students support employees disabilities health conditions backgrounds benefited gsk stem equity grants additionally disability confidence training added provided local nonprofit organisations far first line leader training aimed people managers uk launched million year stem equity training designed develop inclusive leaders able programme targeting yearold girls young women promote disability confidence within teams black people people low socioeconomic backgrounds continue work make sure lgbtq colleagues programme includes nationwide stem mentoring delivered feel welcome valued included partnership established mentoring organisations first recognised gold employer within stonewalls top global three years aim reach approximately young people employers index programme gender diversity women employees svpvp level pr director level manager level total women management women board share women stemrelated positions total stem positions women management positions revenuegenerating functions pr metric contributes esg performance rating metrics data independently assured data represents actively responded identify gender category actively respond indicated prefer say gsk esg performance report march approach access global health environment dei ethical standards product governance appendix diversity equity inclusion continued svpvp director manager employees us ethnic diversity american indian alaska native asian black pr african american hispanic pr latinx native hawaiian pacific islander two races ethnically pr diverse total white total uk ethnic diversity asian black pr mixed ethnically pr diverse total white total pr metric contributes esg performance rating metrics data independently assured data represents responded identify race ethnicity category us employees actively respond identify race ethnicity category indicated prefer say uk actively respond indicated prefer say due rounding sum data may marginally different totals nsufficient data report fewer three employees gsk esg performance report march approach access global health environment dei ethical standards product governance appendix ethical standards culture guides people behave ethical way right thing speak concerns expect everyone works us live expect suppliers employees completed employees believe direct highrisk suppliers mandatory training 'can speak achieved minimum things n't feel right ' ecovadis score commitment promote ethical behaviour across business supporting percentage employees believe speak employees right thing working suppliers things dont feel right general industry share standards operate responsible way benchmark percentage direct highrisk suppliers achieve gsks esg performance rating metrics minimum ecovadis score improvement plan percentage employees complementary workers place complete gsks mandatory training supporting gsk people right thing important people everyone works approach managing abac risk risks relating behalf conducts right way builds trust ethical standards forms part wellembedded risk protects business helps create workplace management framework described detail thrive things important annual report pages code conduct code reflects purpose unite g skcom antibribery corruption policy code science technology talent get ahead disease together sets commitments make company reporting investigating concerns deliver purpose ambition code anyone inside outside gsk raise concerns speak supported additional global policies standards integrity lines confidentially anonymously without fear found code hub accompanying global retaliation take every concern seriously review every mandatory learning curriculum living code report see whether need investigate formally people required complete comprising three modules investigations show employee breached policies code creating inclusive workplace protecting gsk take action protecting gsk focuses key areas antibribery saw overall decrease number employees corruption abac information cyber security privacy concerns raised employees disciplined reporting human safety information related products policy violations open cases year end reflective speak integrity lines employees several factors including external geopolitical economic complementary workers completed training issues affecting countries changes nature due year end concerns raised internally continued emphasis additional abac training people certain appropriate management closure cases highrisk roles geographic regions helps identify mitigate potential abac risk especially thirdparty relationships recognise report manage conflicts interest employees complementary workers completed training due year end general industry benchmark according research kornferry gsk esg performance report march approach access global health environment dei ethical standards product governance appendix ethical standards continued commitment human rights committed respecting internationally recognised conduct audits site visits covering ehs labour rights human rights wherever business salient human rights priority suppliers issues identified relate access healthcare research practices patient safety supplier visits related policy wages compliance environment health safety ehs privacy continue observations action plans place drive improvement make progress integrating within operations tracked followed completion conduct business committed fair equitable pay ensuring signatories un global compact human employees globally receive pay competitive local rights position statement lays commitment un markets sufficient support sustainable standard living guiding principles business human rights fair wage network certified gsk living wage crossbusiness human rights steering group reports employer reviewed global gap analysis conducted gsk leadership team boards corporate responsibility confirmed gsk workers paid committee drives progress human rights impacts living wage relevant markets also developed risks across business consistent approach gsk manage global fair wage analysis annually well methodology fair wage carried human rights training priority suppliers network use continue assess us aimed ensuring good understanding human rights labour principles aligned international standards also g skcom position human rights modern slavery act statement continued human rights training procurement third position working third parties party engagement leads better equip spot human rights issues visiting suppliers working third parties suppliers third parties including agents assess third parties understand whether consider distributors affiliate companies equity low medium high risk highrisk third parties stake help us research develop manufacture distribute determined location highrisk markets size spend medicines vaccines patients need want work type goods services mostly goods services business partners share commitment high ethical providers distributors wholesalers direct material standards operate responsible way third suppliers contract manufacturers parties act direct impact us important assessed highrisk third parties totalling manage relationships well including way assessments across risk areas also use tools assess choose contract monitor suppliers manage risks including ecovadis desktop assessments thirdparty risk management programme provides additionally support ongoing oversight third framework manage oversee risks associated parties suppliers additional controls monitoring third parties engage provide goods services programmes ensure meet standards expect third parties comply applicable laws requirements example include controls relevant regulations adopt minimum abac labour principal risks manage thirdparty risk differs rights principles relevant comply standards business area according thirdparty risk profiles teams quality patient safety health safety environment global supply chain business responsible onsite expectations formalised contracts subject supplier visits audits periodic business review appropriate levels audit oversight new suppliers performance meetings annual semiannual enterprise undergo risk assessment existing suppliers level governance rd established thirdparty assessed every three years average appropriate action monitoring programme assess compliance policies taken third parties found breach standards commercial business annually risk undertakings assess key commercial third parties prioritise independent monitoring reviews focused abac commercial practices scientific patient engagement monitor actions require complete reasons ur largest suppliers including supply globally medically critical products critical rd largest spend gsk esg performance report march approach access global health environment dei ethical standards product governance appendix ethical standards continued helping suppliers manage environment conducted supplier audits following industry standard pharmaceutical supply chain initiative guidelines trained health safety risks supplier employees ehs esg across organisation give additional support ehs risks fundamentals year strengthened ehs contractual obligations largest suppliers including supply globally worked suppliers help improve medically critical products critical rd ecovadis scores introduced process pause supply largest spend help suppliers improve safety management third party significant ehs incident decision systems build overall ehs capability focusing active whether restart discontinue work third party pharmaceutical ingredients manufacturers contract depends completion improvement plan trajectory manufacturing suppliers also introduced ehs risk appbased questionnaire gsk set ehs requirements review performance part visitors third party part monitoring activities internal ehs governance oversight visit sites person generate improvement actions track virtually help suppliers better understand control completion risks year conducted physical visits across priority suppliers g skcom position working third parties annual report principal risks uncertainties pages using data ai responsibly data essential foundation realising ambitions created crossfunctional ai governance council patients advances artificial intelligence ai machine oversee ai strategy ensure responsible adoption learning ml technologies present tremendous opportunities aiml complemented internal policy ensure technologies must approached correctly responsibly aiml adoption safe aligned gsks culture ethically increases volume data processed ai establishing ai principles underpinned ethical ml use resulted greater focus data governance standards set gsk code ai governance council ethical use personal information responsible enforcing ai principles monitoring compliance data privacy laws external aiml landscape anticipate potential risks gsk take responsibility data privacy seriously also published public policy position responsible ai exercise high standards integrity dealing personal set views commitments asks policymakers information employees patients clinical research new operating model ai governance scalable flexible participants healthcare providers stakeholders adapt upcoming regulations engaging policymakers appropriate regulatory approaches digital privacy governance board oversees overall foster innovation preserving safety trust data ethics privacy operating model supported digital privacy legal experts compliance professionals monitor g skcom annual report pages annual report rd pages mitigate new emerging cyber threats protect gsk position responsible ai cyber security risks additional governance boards oversee use data research development manufacture supply products ensure follow regulations meet ethical obligations political engagement industry heavily regulated meaning business committed highest ethical standards legislative model market influenced legislation regulation requirements political engagements make gsk seek contribute public policy debate especially corporate political contributions sponsor party political relation life sciences healthcare major multinational meetings anywhere around world company frequently invited governments give g skcom position political advocacy political advocacy views development new policies along disclosure stakeholders nongovernmental organisations scientists healthcare professionals patients industry groups g sk maintains list globally medically critical products drug products approved treat lifethreatening disease medical condition adequately available alternative gsk provider ehs priority suppliers api suppliers medically rd revenuecritical gsk highspend suppliers gsk esg performance report march approach access global health environment dei ethical standards product governance appendix eetthhiiccaall ssttaannddaarrddss ccoonnttiinnuueedd ethical conduct employees concerns raised including current year prior year open cases employees disciplined policy violations breakdown types policy violation employee conduct sales marketing product quality safeguarding people information assets employee relations hr policies rd medical practices antibribery corruption cyber security ehs sustainability employees dismissed agreed leave company voluntarily result misconduct documented warnings open cases awaiting investigation disciplinary decision year end mandatory training employees complementary workers complete gsks mandatory training pr employees complete gsks mandatory training code living values expectations working gsk complementary workers complete gsks mandatory training code living values expectations working gsk employees complete gsks mandatory training abac complementary workers complete gsks mandatory training abac reporting concerns employees believe speak things dont feel right pr suppliers direct highrisk suppliers achieve gsks minimum ecovadis score pr improvement plan place pr metric contributes esg performance rating metrics data independently assured enhanced analytics types discipline taken identified additional cases prior years disciplinary action reported result restated prior years metrics following net increase changes employees disciplined policy violations prior reporting disciplinary action taken within year n updated reporting methodology breakdown types policy violation provide granularity case class broader distribution top five policy area categories historically reported 'other ' enable comparison prior year data restated using new reporting methodology n changed process circumstances trigger discipline late completion mandatory training reported employee conduct result saw fewer disciplinary cases compared prior years n changes prior years reflective several factors including external geopolitical economic issues affecting countries changes nature concerns raised internally continued emphasis appropriate management closure cases correlating increase areas n policy violation class type name changed computer databreach security cyber security contentclassification remains therefore data comparable year year majority ehs sustainability category increases written warnings related compliance company 's covid vaccination mandate safety testing requirements ensure health safety wellbeing workforce subsequently lifted april correlating decrease hese figures based active employees complementary workers year end data split employees complementary workers disclosed prior esg reports rounded nearest whole number also includes data previous consumer healthcare business due attrition last three years restating completion rates would provide comparable metric updated way report completion mandatory training combining metrics employees complementary workers across mandatory trainings single metric rounded nearest whole number gsk esg performance report march approach access global health environment dei ethical standards product governance appendix ethical standards continued supplier spend region asiapacific europe middle east africa latin america north america us political engagement spend federal lobbying activities trade association membership spend corporate political contributions political action committee contributions us employees state federal candidates ' european political engagement trade association membership spend corporate political contributions cost representing interests eu institutions pr metric contributes esg performance rating metrics data independently assured g sk make corporate political contributions sponsor political meetings anywhere around world includes latest available figures previous year figures reporting year published annually march publication document e uropean political memberships included efpia european federation pharmaceutical industries associations abpi association british pharmaceutical industry gsk esg performance report march approach access global health environment dei ethical standards product governance appendix product governance protect patients critically important ensure quality safety reliable supply products quality audits regulatory inspections clinical trial protocol contract manufacturers manufacturing sites local summaries registered suppliers operating companies summaries results commitment commit maintaining robust quality safety processes number fda warning letters using data new technologies responsibly total number class iii external product recalls across markets esg performance rating metrics register disclose human subject research gsk average number critical major findings per inspection products specifically register protocol summaries studies fdamhraema regulators initiated disclose results summaries studies percentage inspections regulators critical results due findings official action indicated product quality patient safety critically important gsk systems enable us deliver safe reliable supply systems place across company ensure highquality medicines vaccines issues arise meet high standards set quality systems line valuesdriven culture ensure expected us externally responded swiftly transparently maintaining quality across gsk detailed specific quality framework describes inspections recalls audit comply regulatory requirements standards subject frequent regulatory inspections markets across markets addresses global local regulations supply medicines vaccines inspections across manufacturing distribution processes based provide independent assurance development principles defined international council harmonisation manufacturing distribution processes adhere required technical requirements pharmaceuticals human use high quality standards expectations work ensure gsk quality function responsible managing quality inspection ready times ensuring quality mindset embedded throughout regulatory inspections manufacturing organisation levels brings together extensive global sites local operating companies compared network quality compliance professionals within received zero warning letters united states food business units site level senior management drug administration fda critical findings medicines quality management system provides standards required healthcare products regulatory agency mhra followed gsk people support good distribution european medicines agency ema respond manufacturing practice maintain standardised learn inspection findings taking necessary actions compliant approach quality activities aligned address regulatory expectations markets supply throughout two class product recalls instances engaged regulators acted quickly prioritise patient safety fewer class ii recalls compared necessary protect patients hesitate recall products voluntarily consider observations us fda major gsk esg performance report march approach access global health environment dei ethical standards product governance appendix product governance continued quality management along supply chains comprehensive quality oversight model suppliers aligned quality management system uses expect contract manufacturers suppliers riskbased approach assess qualify manage monitor comply gsk standards conducted quality thirdparty suppliers ongoing basis driving continuous audits contract manufacturers suppliers verify performance pharmacovigilance wellestablished rigorous worldwide system tackling counterfeit medicines vaccines monitor review safety products throughout clinical falsified products put health patients risk threaten development regulatory approval brand reputation report cases confirmed pharmacovigilance system aim enhance patient care counterfeit products relevant regulatory safety using marketed investigational medicines authorities actively participate legal proceedings vaccines also support public health programmes illegal actors support customs local authorities using system provide reliable comprehensive information regular training also monitor online marketplaces social products overall benefitrisk balance media request takedowns sites illicitly selling prescription expect partners meet high standards medicines safety governance conduct reviews thirdparty safety g skcom position falsified substandard healthcare products systems monitoring contractual obligations fostering collaboration life cycle relationship g skcom position pharmacovigilance clinical data transparency committed transparency data clinical studies part commitment transparency made evaluate medicines vaccines want protocol summaries summaries results available since enable access information research study gsk trial register set also listed participants patients healthcare providers wider public clinical trials data sharing via wwwvivliorg also allows us acknowledge invaluable contribution people take part clinical research regulatory inspections audits audits third parties quality processes total regulatory inspections health authorities pr inspections regulators critical findings official action indicated pr total regulatory inspections fdamhraema regulators pr number criticalmajor findings fdamhraema regulators pr total fda regulatory inspections pr number fda observations pr number fda warning letters pr product recalls total number class external product recalls pr total number class ii external product recalls pr total number class iii external product recalls pr total product recalls pr metric contributes esg performance rating metrics data externally assured figure restated gsk esg performance report march approach access global health environment dei ethical standards product governance appendix product governance continued fda product recalls business class pharmaceuticals business class product recalls pr class ii product recalls pr class iii product recalls vaccines business class product recalls pr class ii product recalls pr class iii product recalls clinical trial management pharmacovigiliance transparency clinical trial audits trials conducted third parties behalf number fda sponsor inspections related clinical trial management pharmacovigilance resulted voluntary action indicated vai number fda sponsor inspections related clinical trial management pharmacovigilance resulted official action indicated oai clinical study reportsstudy report synopsis gsk viiv study register trials anonymised data made available upon meeting defined eligibility criteria research proposals approved access gsk viiv clinical trial data human subject research gsk products percentage protocol summaries initiated current pr year registered results disclosed current year publicly available trial protocol summaries register pr publicly available trial result summaries disclose pr pr metric contributes esg performance rating metrics data independently assured data includes recalls us market may initiated voluntarily gsk requested us fda mandated us fda statutory authority includes viiv healthcare addition gsk metric created first reported number protocol summaries registered results summaries disclosed independently assured c umulative summaries gsk cumulative viiv healthcare gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix materiality assessment gsk conducted materiality assessment process process issues identified material engagement analysis identifies prioritises business external stakeholders illustrated esg issues pose significant risks opportunities matrix issues identified process helped business gsk significant impact confirm six esg focus areas access global health health materiality assessment used inform strategic decision security environment diversity equity inclusion ethical making helps us prioritise issues covered public reporting standards product governance used datamarans data analytics platform conduct read materiality methodology process assessment software monitors external esg risks key observations please see materiality overview gskcom assessing coverage issues within peer annual g skcom materiality assessment sustainability reports regulatory legislative documents media social media also conducted stakeholder engagement internal external interviews analysis investor ratings rankings reports medium high importance business gsk esg performance report march sredlohekats lanretxe ot ecnatropmi materiality matrix high product quality privacy patient safety data security supply chain management product innovation global health security labour rights healthcare access affordability ethical business conduct employee health safety wellbeing clinical trial conduct climate change talent attraction retention nature environmental protection waste hazardous materials management diversity equity water wastewater management inclusion key access environment ethical standards global health diversity equity product governance health security inclusion people cultureour approach access global health environment dei ethical standards product governance appendix appendix continued people disclosures positive experience work critical attract retain keeping people safe motivate best people want workplace embrace care deeply health safety employees everyones unique differences encourage growth complementary workers everyone works visits development safe environment people perform sites commitment everyone goes home safely best work information around put life saving rules embedded throughout company people heart success please see rules simple standardised easy remember detail focus diversity equity inclusion responsibilities safety leaders individuals see reviewed levels organisation risk assessments key part environment health safety control freedom association framework governs approach identifying respectful right colleagues join controlling hazards conduct health safety training independent trade union collectively bargain freedom people specific whether working office association global employee population lab manufacturing site commercial operations covered collective bargaining arrangements recent key initiatives included safety leadership warehouse declared member union also invest safety driver safety improved reporting heavily formal information consultation arrangements processes systems carried increased training actively involve provide additional employee voice safety incident reporting contributed uplift higher proportion colleagues reported injuries illnesses lost time g skcom policy environment health safety hiring total number new hires open positions filled internal candidates employee turnover overall turnover turnover voluntary leavers permanent leavers male permanent leavers female workforce breakdown age permanent employees years old years old years old engagement employee surveys engagement score talent leadership development number graduates recruited future leaders programme number postgraduates recruited esprit programme number apprentices recruited metrics data independently assured n certain markets data unavailable due privacy reasons c alculated number permanent employees voluntarily left gsk divided average permanent headcount reporting year c alculated number permanent employees left gsk reason within period male female divided total number permanent leavers left reason within period e mployee surveys response rate gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued health safety number fatalities employees complementary workers gsk direct supervision number fatalities contractors gsk direct supervision reportable injuries lost time reportable illnesses lost time lost time reportable injury rate per hours worked lost time reportable illness rate per hours worked reportable injuries without lost time reportable illnesses without lost time reportable injury rate per hours worked reportable illness rate per hours worked reportable injury illness rate per hours worked hours worked metrics data independently assured two illnessrelated incidents involved multiple workers promptly investigated corrected totals may equal exact sum constituents due rounding gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued gri guidelines sasb index gri indicator description find information general disclosures organisational details legal name gsk plc ownership annual report share capital share price hq address brentford middlesex tw gs uk operations annual report business model pages entities included organisations sustainability reporting gsk plc reporting period frequency contact point sustainability financial annual reporting period january december report publication march contact csrcontactgskcom restatements information demerger comparative results restated reflect demerger consumer healthcare business unless otherwise specified restatements information detailed relevant specific data points throughout report external assurance independent limited assurance statements pages activities value chain business relationships sector healthcare pharmaceuticals annual report business model pages changes compared previous reporting period following demerger consumer healthcare business form haleon july fully focused biopharma company employees fulltime employees ftes december annual report employees gender changes compared previous reporting period following demerger consumer healthcare business form haleon july fullyfocused biopharma company workers employees reported governance structure composition annual report board gsk leadership team annual report corporate governance architecture annual report nominations corporate governance nomination selection highest governance body committee report pages chair highest governance body gsk independent nonexecutive chair board role highest governance body overseeing annual report corporate responsibility committee report management impacts delegation responsibility managing impacts annual report corporate responsibility committee report role highest governance body sustainability reporting esg performance report reviewed gsk leadership team board conflicts interest annual report directors conflicts interest communication critical concerns annual report board committee reports collective knowledge highest governance body annual report board evaluation performance highest governance body annual report board performance remuneration policies annual report annual report remuneration pages process determine remuneration annual report annual report remuneration pages annual total compensation ratio annual report annual report remuneration statement sustainable development strategy annual report ceo 's statement policy commitments policy positions including human rights policies approved gsk leadership team level apply grouplevel embedding policy commitments corporate responsibility committee processes remediate negative impacts annual report principal risks uncertainties ethical standards ethics compliance grievance mechanisms gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued gri indicator description find information mechanisms seeking advice raising concerns ethical standards esg performance report grievance mechanisms compliance laws regulations annual report audit risk committee report membership associations trade association memberships approach stakeholder engagement esg performance report stakeholder engagement collective bargaining agreements people disclosures position human rights process determine material topics materiality assessment esg performance report list material topics materiality assessment esg performance report management material topics materiality assessment esg performance report economic performance direct economic value generated distributed annual report financial statements financial implications risks opportunities due annual report risk management climate change annual report tcfd defined benefit plan obligations retirement plans annual report annual report remuneration financial assistance received government annual report financial statements annual report share capital control anticorruption operations assessed risks related corruption annual report risk management communication training anticorruption policies ethical standards esg performance report pages procedures confirmed incidents corruption actions taken ethical standards esg performance report pages tax approach tax gsk tax strategy tax governance control risk management gsk tax strategy stakeholder engagement management concerns gsk tax strategy related tax countrybycountry reporting gsk tax strategy energy energy consumption within organisation environment esg performance report environment basis reporting environmental data energy consumption outside organisation environment esg performance report environment basis reporting energy intensity annual report tcfd pages environment basis reporting reduction energy consumption environment esg performance report pages environment basis reporting reductions energy requirements products services environment esg performance report pages environment basis reporting water interactions water shared resource environment esg performance report pages annual report tnfd management water dischargerelated impacts environment basis reporting water withdrawal environment esg performance report pages annual report tnfd environment basis reporting water discharge environment esg performance report pages annual report tnfd environment basis reporting water consumption environment esg performance report pages annual report tnfd environment basis reporting gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued gri indicator description find information biodiversity management material topics materiality assessment esg performance report operational sites owned leased managed adjacent annual report tnfd protected areas areas high biodiversity value outside protected areas significant impacts activities products services environment esg performance report pages biodiversity annual report tnfd pages habitats protected restored environment esg performance report pages annual report tnfd pages iucn red list species national conservation list species reported habitats areas affected operations emissions direct scope ghg emissions environment esg performance report environment basis reporting environmental data energy indirect scope ghg emissions environment esg performance report environment basis reporting environmental data indirect scope ghg emissions environment esg performance report environment basis reporting environmental data ghg emissions intensity annual report tcfd environment basis reporting environmental data reduction ghg emissions environment esg performance report pages environment basis reporting environmental data emissions ozonedepleting substances ods environment esg performance report environment basis reporting environmental data nitrogen oxides nox sulfur oxides sox significant reported air emissions waste waste generation significant wasterelated impacts environment esg performance report pages management significant wasterelated impacts environment esg performance report pages environment basis reporting waste generated environment esg performance report pages environment basis reporting waste diverted disposal environment esg performance report pages environment basis reporting waste directed disposal environment esg performance report pages supplier environmental assessment new suppliers screened using environmental ethical standards esg performance report pages criteria negative environmental impacts supply chain ethical standards esg performance report pages actions taken employment new employee hires employee turnover people disclosures esg performance report pages benefits provided fulltime employees life gsk provided temporary parttime employees parental leave reported occupational health safety occupational health safety management system gsk ehs policy hazard identification risk assessment incident gsk ehs policy investigation occupational health services gsk ehs policy worker participation consultation communication gsk ehs policy occupational health safety worker training occupational health safety gsk ehs policy promotion worker health gsk ehs policy prevention mitigation occupational health safety gsk ehs policy impacts directly linked business relationships gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued gri indicator description find information workers covered occupational health safety gsk ehs policy management system workrelated injuries people disclosures esg performance report pages gsk ehs policy workrelated ill health diversity equal opportunity diversity governance bodies employees diversity equity inclusion people disclosures esg performance report pages ratio basic salary remuneration women men gender pay gap report diversity equity inclusion nondiscrimination management material topics materiality assessment esg performance report human rights labour rights operations suppliers right freedom gsk position human rights association collective bargaining may risk operations suppliers significant risk incidents gsk position human rights child labour modern slavery act statement operations suppliers significant risk incidents gsk position human rights forced compulsory labour modern slavery act statement new suppliers screened using social criteria ethical standards esg performance report pages negative social impacts supply chain actions ethical standards esg performance report pages taken public policy political contributions political advocacy disclosure customer health safety assessment health safety impacts product product governance esg performance report service categories pages incidents noncompliance concerning health product governance esg performance report safety impacts products services pages customer privacy management material topics materiality assessment materiality assessment esg performance report marketing labelling requirements product service information code practice labelling incidents noncompliance concerning product service product governance esg performance report information labelling pages incidents noncompliance concerning marketing product governance esg performance report communications pages sasb indicator description find information safety clinical trial participants hcbpa discussion region management process ensuring position approach clinical trials quality patient safety clinical trials hcbpa number inspections related clinical trial management clinical data transparency esg performance report pharmacovigilance resulted entity voluntary pages remediation regulatory administrative actions taken available via fda inspection citation entity access medicines hcbpa description actions initiatives promote access access esg performance report pages health care products priority diseases priority countries defined access medicine index hcbpa list products list prequalified medicinal list products esg performance report products part prequalification medicines global health health security esg performance report programme pqp pages gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued sasb indicator description find information affordability pricing hcbpb percentage change weighted average list price access esg performance report weighted average net price across product portfolio compared previous reporting period hcbpb percentage change list price net price access esg performance report pages product largest increase compared previous reporting period drug safety hcbpa products listed public medical product safety adverse available via fda event alert databases hcbpa number fatalities associated products available via fda hcbpa number recalls issued total units recalled product governance esg performance report pages hcbpa total amount product accepted takeback reuse reported disposal hcbpa number enforcement actions taken response esg performance report inspections recalls audit violations good manufacturing practices gmp equivalent standards type counterfeit drugs hcbpa description methods technologies used maintain product governance esg performance report traceability products throughout supply chain pages prevent counterfeiting position falsified substandard healthcare products hcbpa discussion process alerting customers business product governance esg performance report partners potential known risks associated pages counterfeit products position falsified substandard healthcare products hcbpa number actions led raids seizure arrests andor reported filing criminal charges related counterfeit products ethical marketing hcbpa total amount monetary losses result legal reported proceedings associated false marketing claims hcbpa description code ethics governing promotion code practice promotional nonpromotional external offlabel use products interactions employee recruitment development retention hcbpa discussion talent recruitment retention efforts culture people esg performance report scientists research development personnel hcbpa voluntary involuntary turnover rate people disclosures esg performance report executivessenior managers b midlevel managers c professionals others supply chain management hcbpa percentage entitys facilities tier suppliers gsk member rx also conducts audits third facilities participating rx international parties pharmaceutical supply chain consortium audit programme working third parties esg performance report equivalent thirdparty audit programmes integrity supply chain ingredients business ethics hcbpa total amount monetary losses result legal reported proceedings associated corruption bribery hcbpa description code ethics governing interactions engagement healthcare professionals healthcare professionals activity metrics hcbpa number patients treated access esg performance report pages patients reached access strategies hcbpb number drugs portfolio research annual report product development pipeline development phases gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued list products list prequalified medicinal products vaccines part prequalification medicines programme pqp type form presentation date prequalification vaccines engerix hepatitis b liquid ready use vial one dose thursday january engerix hepatitis b liquid ready use vial doses thursday january engerix hepatitis b liquid ready use vial doses thursday january priorix measles mumps rubella lyophilised active component reconstituted friday march excipient diluent use vial one dose rotarix rotavirus liquid ready use plastic tube one dose thursday march rotarix rotavirus liquid ready use applicator one dose thursday march cervarix human papillomavirus bivalent liquid ready use vial one dose wednesday july cervarix human papillomavirus bivalent liquid ready use vial two doses wednesday july polio sabin mono polio vaccine oral opv monovalent type liquid ready use vial doses thursday october polio sabin mono polio vaccine oral opv monovalent type liquid ready use vial doses thursday october polio sabin one three polio vaccine oral opv bivalent types liquid ready use vial doses thursday october polio sabin one three polio vaccine oral opv bivalent types liquid ready use vial doses thursday october synflorix pneumococcal conjugate liquid ready use vial one dose friday october synflorix pneumococcal conjugate liquid ready use vial two doses friday march polio sabin mono three oral polio vaccine oral opv monovalent type liquid ready use vial doses tuesday october polio sabin mono three oral polio vaccine oral opv monovalent type liquid ready use vial doses tuesday october polio sabin mono two oral polio vaccine oral opv monovalent type liquid ready use vial doses wednesday may polio sabin mono two oral polio vaccine oral opv monovalent type liquid ready use vial doses wednesday may priorix measles mumps rubella lyophilised active component reconstituted wednesday december excipient diluent use vial two doses hepatitis human diploid cell inactivated adult liquid ready use vial havrix adult friday july one dose havrix junior hepatitis human diploid cell inactivated paediatric liquid ready use vial friday july one dose boostrix diphtheriatetanuspertussis acellular liquid ready use vial one dose tuesday july menveo meningococcal acyw conjugate vaccine lyophilised active component wednesday july reconstituted liquid active component use two vial set one dose synflorix pneumococcal conjugate liquid ready use vial four doses monday october rotarix rotavirus liquid ready use plastic tube five doses thursday february mosquirix plasmodium falciparum malaria hepatitis b recombinant adjuvanted friday july liquid active component mixed second component use two vial set two doses pharmaceuticals abacavir sulfate hiv viiv healthcare ha march abacavir sulfate hiv viiv healthcare ha march zidovudine hiv viiv healthcare ha may zidovudine hiv viiv healthcare ha may lamivudinezidovudine hiv viiv healthcare ha march zidovudine hiv viiv healthcare ha march zidovudine hiv viiv healthcare ha march lamivudine hiv viiv healthcare ha march lamivudine hiv viiv healthcare ha march dolutegravir sodium hiv viiv healthcare ha october abacavir sulfatelamivudine hiv viiv healthcare ha june dolutegravir sodium hiv viiv healthcare ha july cabotegravir sodium hiv viiv healthcare ha december cabotegravir sodium hiv viiv healthcare ha december zanamivir influenza gsk september gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued esg reporting criteria unless stated otherwise data reflects reporting period january december kpi definition method access total community donations made gsk globally donations included voluntary charitable purpose investment charitable purposes including cash product donations valued gbp year end exchange rates kind donations value time donated via product donations valued global average cost goods reported volunteering management costs yearend results associated charitable programmes inkind donations valued value cost item gsk current external purchase price previous years data included comparison restated inflation exchange rate changes methodology used follows bsi formerly lbg framework corporate community investment value gsk medicine value medicine vaccines provided gsk viiv patient assistance programs foundation administers vaccines provided gsk viiv healthcare patient patient assistance programs patients us puerto rico us us patient assistance programs foundation provides virgin islands assistance program medication charge eligible individuals capture patient assistance program orders gsk viiv cogs million usd patients receive medications healthcare products internal ordering database data patient assistance programs must meet captured according wholesale acquisition cost medicine eligibility requirements requirements vaccine coded free good charitable orders amount include insurance status financial component converted cost goods sold amount reporting purposes based federal poverty level patient participation varies annually based current program eligibility resident us puerto rico us virgin criteria overall healthcare environmental factors products included islands treated uslicensed programs healthcare provider doses rotarix number doses rotarix synflorix calculate number doses supplied use number gsk synflorix cervarix cervarix vaccine supplied gavi doses shipped gavi supported countries vaccines supplied vaccine alliance gsk gavi supplier since gavis inception gavi millions doses mosquirix number doses mosquirix rtss calculate number doses supplied use number gsk rtssas e e vaccine gsk donated malaria doses procured unicef mvip gavi funded supply vaccines supplied vaccine implementation programme mvip gsk supplieddonated million mosquirix rtssas e since millions number gavi funded doses supplied beginning mvip supplied first gavi funded doses gaviunicef q doses opv number doses opv vaccine calculate number doses opv stockpile use number vaccines readyto readytoship stockpile outbreak mopv doses stored gsk warehouse outbreak responses ship stockpile responses unicef outbreak responses unicef millions doses opv number doses opv vaccine calculate number doses supplied use total number gsk vaccines supplied supplied unicef doses shipped countries procuring via unicef routine unicef millions vaccination campaigns outbreak responses people access total number people living hiv chronic ongoing treatment capture cumulative number generic dolutegravir currently accessing generic dolutegravirbased people access dolutegravir rather annual data avoid product products viiv healthcares voluntary duplication indicator therefore represents total number people voluntary licensing licensing agreements medicines patent living hiv accessing treatment time measurement agreements pool directly aurobindo pharma lifelong treatment number incorporates people receiving ongoing treatment multiple years adults living hiv number calculated adding total number packs generic dolutegravirbased products indicated adults sold previous four quarters divided twelve obtain average monthly sales estimate number adults treatment children living hiv done calculating total number paediatric dtg mg tablets sold previous four quarters dividing calculate average number tablets sold per day divided average daily number tablets taken across different paediatric weight bands estimate number children treatment cases packs converted pack equivalents ie monthly equivalents daily treatment data provided medicines patent pool aurobindo viivs dtg patents sublicensed gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued kpi definition method access estimated children estimated number children calculate estimated number children reached use number reached synflorix received synflorix vaccine prevention gsk doses shipped gavi supported countries divide gavi pneumococcal infection gavi number doses needed complete full schedule gavi estimated vaccine alliance vaccine wastage rates factored synflorix full schedule three children receiving synflorix five doses gavi estimates wastage years age see detailedproductprofilesxlsx livecom estimated children estimated number children calculate estimated number children reached use number reached rotarix received rotarix vaccine prevention gsk doses shipped gavi supported countries divide gavi rotavirus gavi vaccine alliance number doses needed complete full schedule gavi estimated vaccine wastage rates factored rotarix full schedule two doses children receiving rotarix five gavi estimates wastage years age see detailedproductprofilesxlsx livecom estimated girls estimated number girls calculate estimated number girls reached use number gsk reached cervarix received cervarix vaccine prevention doses shipped gavi supported countries divide number gavi cervical cancer gavi vaccine doses needed complete full schedule gavi estimated vaccine alliance wastage rates factored cervarix full schedule either one dose two doses gavi estimates wastage see detailedproduct profilesxlsx livecom estimated people estimated number people calculate estimated number people reached use number reached oral received opv vaccine polio procured bivalent opv bopv monovalent opv mopv doses shipped polio vaccine opv unicef unicef divided number doses needed complete full schedule estimated vaccine wastage rates factored outbreak situations gsk opv volumes often used dose usually given child however primary schedule doses children may receive one dose subsequent outbreak campaigns use doses calculation order conservative estimates wastage given supply dose vials vials mainly used campaigns vials may may used discarded vial opened end session see indicative vaccine wastage rates opv supply revisingwastageconcept notepdf whoint estimated people estimated number children calculate estimated number children reached use number reached received rtss vaccine malaria gsk doses shipped divide number doses needed mosquirix rtssas vaccine implementation programme mvip complete full schedule doses estimated vaccine wastage e ' gaviunicef rates dose vials used routine immunisation factored see detailedproductprofilesxlsx livecom albendazole tablets number albendazole tablets donated albendazole tablet shipments sent gsks manufacturing facility donated help world health organization support endemic countries shipments entered realtime database eliminate lymphatic endemic country efforts eliminate lymphatic donated medicines neglected tropical diseases albendazole tablet filariasis millions filariasis lf donation figures lf aggregated reported annually data pulled system albendazole tablets number albendazole tablets donated albendazole tablet shipments sent gsks manufacturing facility donated help treat world health organization support endemic countries shipments entered realtime database intestinal worms endemic country efforts treat soil donated medicines neglected tropical diseases albendazole tablet millions transmitted helminthiasis intestinal worms donation figures soiltransmitted helminthiasis control aggregated schoolage children reported annually data pulled system people reached total number unique individuals gsk viiv patient assistance programs foundation administers us patient received gsk viiv healthcare product patient assistance programs patients us puerto rico us assistance program patient assistance programs virgin islands patients receive medications us patient assistance programs provides report yearend patient assistance programs must meet eligibility enables us consolidate number unique patients received requirements requirements include gsk viiv healthcare products throughout year insurance status financial component based patient participation varies annually based current programme eligibility federal poverty level resident criteria overall healthcare environmental conditions products included us puerto rico us virgin islands programmes treated uslicensed healthcare provider gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued kpi definition method global health health security number assets number assets progressed pipeline progression defined movement global health asset progressed global health pipeline address priority one phase another gsk recognises progression global health diseases across gsks two global health hubs following four categories pipeline address tres cantos spain focuses senior leadership endorsement business plan progression priority diseases therapeutics gsk vaccines institute clinical trial starts first subject first visitdose global health gvgh sienna focuses business developmentinlicensing preventative treatment regulatory milestone ie submission approval launch priority diseases defined diseases esg achievements consider gsks internal week grace period pathogens prioritized rd public ensure asset progressed january double health emergency contexts distinguishes counted metric diseases degree pose greatest public health risk due epidemic potential andor whether insufficient countermeasures gsk uses following lists priority pathogen list emergency diseases list blueprint prioritized disease list essential medicines list un sustainable development goals reviews updates lists needs arise methodologies change number active rd number active rd projects address active rd projects include projects discovery preclinical phase projects address pathogens prioritised cdc phase ii phase iii open label trials pathogens prioritised posing highest level concern due drug global infectious disease vaccines team maintain internal cdc resistance critical andor urgent threats tracker active projects run exclusively gsk additional posing highest gsk uses following lists define critical projects run partner companies added list level concern due andor urgent threats accuracy validated key subject matter experts identified drug resistance critical andor urgent bacterial pathogens categorized controls document threats critical threats updated fungal pathogens categorized critical threats added pathogens listed urgent threats cdc updated active rd projects include rd projects id therapeutics vaccines team includes active rd projects discovery preclinical phase phase ii phase iii open label trials note projects clinical hold low prioritytier projects included count currently cdc designated critical andor urgent threats include carbapenem resistant cr acinetobacter spp c difficile cr esbl enterobacteriaceae drugresistant n gonorrhoeae carbapenemresistant p aeruginosa candida auris candida albicans aspergillis fumigatus cryptococcus neoformans environment full list environment reporting criteria please see basis reporting including full definitions methodologies diversity equity inclusion ethnically diverse total total percentage ethnically diverse data covers total number employees salaried internal hr employees gsk us uk employee system active including fulltimeparttime regulartemporary population across svpvp level director level employees nonactive ie maternity leave paternity leave manager level across employees due adoption leave etc excludes puerto ricobased employees agency differing ethnic groups across uk temporary workers contingent workers defined payrolled via us employee population raceethnic recruitment agencies employees blank ethnicity prefer categories defined according uk say us figures exclude puerto ricobased employees given significant census us federal reporting guidelines differences ethnic composition territorys population relative rest us percentage calculated using employee numbers december current year calculated number salaried employees december current year recorded internal hr system selfidentified ethnically diverse divided total salaried employees system gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued kpi definition method diversity equity inclusion total women total percentage women data covers total number salaried employees identify management management role management classed women within hr system including active fulltimeparttime employee grade bands includes regulartemporary employees nonactive ie maternity leave managers directors vps svps paternity leave adoption leave etc excludes agency temporary workers contingent workers defined payrolled via recruitment agencies employees gender recorded indicated prefer say percentage calculated using employee numbers december current year calculated number salaried employees december recorded hr system gender specified female within grades divided total payrolled employees recorded hr system phase iii trials total percentage clinical trials number status actual protocol approvals recorded initiated current achieved first subject first visit fsfv gsks electronic trial master file veeva cdms database reporting year study diversity plan recorded time proactive plans fsfv diversity ethical standards employees number distinct employees anyone inside outside gsk raise concerns speak concerns raised disciplinary concern raised independent third party integrity lines confidentially anonymously concerns also raised internally employees management internal monitoring data comprises regular employees excludes contractors contingent workers data includes total number distinct employees disciplinary concern raised reporting period employees disciplinary concerns raised prior years open cases employees disciplined number distinct employees data comprises regular employees excludes contractors policy violations outcome concern raised resulted contingent workers disciplinary action data represents cases closed reporting period also included three open cases disciplinary decisions made action taken year end however cases yet closed source system reporting criteria end date range due timing disciplinary action includes documented warning termination resignation employees number distinct employees data comprises regular employees excludes contractors dismissed agreed outcome disciplinary concern resulted contingent workers leave company termination employment voluntary data represents cases closed reporting period also voluntarily resignation employee included three open cases disciplinary decisions made action taken year end however cases yet closed source system reporting criteria end date range due timing includes termination employment resignation documented number distinct employees data comprises regular employees excludes contractors warnings outcome disciplinary concern resulted contingent workers documented warning data represents cases closed reporting period also included three open cases disciplinary decisions made action taken year end however cases yet closed source system reporting criteria end date range due timing disciplinary action includes documented warning level sanction final warning open cases awaiting number distinct employees involved data comprises regular employees excludes contractors investigation investigation disciplinary decision contingent workers disciplinary decision still open pending outcome data represents employees involved disciplinary case year end end reporting period remain open end reporting period also included three open cases disciplinary decisions made action taken year end however cases yet closed source system reporting criteria end date range due timing outcome investigations still open awaiting disciplinary action year end captured subsequent reporting period correlating metric updated accordingly prior year gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued kpi definition method ethical standards compliance breakdown types policy violations data comprises regular employees excludes contractors breakdown types employees disciplined contingent workers policy violation year individual employees subject multiple allegations resulting policy violations categories defined disciplinary action case individual counted antibribery corruption antibribery unique category corruption employee discipline results policy violation includes level cyber security cyber security csir sanction level sanction level sanction final warning termination continuity supply chain supply chain resignation categorised appropriate outcomes employees continuity including mediation demotion settlement included counts ehs sustainability environment health percentages within categories outcome types considered safety sustainability disciplinary action represent situations employees employee conduct conflict interest company work together towards solution discrimination expenses harassment markets except germany utilise case management system inappropriate behaviour mandatory training manage cases data retention german market maintains employee relations hr policies case list submitted global employee relations team year appeal attendance work capability health end consolidation analysis capability performance external litigation gsk performance system recruitment selection case owners regularly utilise published data quality reports assist restructuring programmes settlementmutual data accuracy regularly quarterly internal audits conducted agreement working arrangements address outstanding data discrepancies government trade restrictions sanctions export controls product quality good manufacturing practice manufacturing site resilience supply chain quality assurance research development medical practices care welfare treatment animals data integrity nongxp good laboratory practicesgood clinical practice human biological sample management hbsm nonpromotional engagement nonpromotional engagement patient safety public disclosure regulatory filings safeguard people information assets communications corporate financial information reporting disclosure crisis continuity management fraud intellectual property privacy loss data privacy unauthorized access privacy unsecured data disclosure protection physical assets security security people security places sites security productssupply chain sales marketing antitrust commercial practices funding contract sales organisation external experts hcphci transfer value inappropriate managerial direction interactions pagsconsumerpayer groups product promotion samples speaker programme tax treasury tax treasury policy violation types fit categories specified employees percentage active employees active employees fulltimeparttime regulartemporary complementary complementary workers complementary workers ie agency workers statement work workers workers complete assigned mandatory training curriculum outsourced workers etc required complete global mandatory gsks mandatory completed training modules learning curriculum called living code comprises two modules training code living code additionally highrisk roles geographic regions complete additional module effectively managing high abac risk percentage calculated using training data december ie training due december calculated total number active employees complementary workers assigned living code mandatory training completed modules divided total population active employees complementary workers assigned living code mandatory training gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued kpi definition method ethical standards employees percentage employees strongly question included annual engagement culture survey believe agreed agreed question sent annually speak things speak things dont feel right gsk survey issued regular fulltime fixed term contract n't feel right annual engagement culture survey employees countries gsk operates excluding russia due sanctions questions translated professional service partners languages excluding english annual engagement culture survey replaced quarterly pulse surveys therefore percentage employees metric result single annual data point instead average score across quarterly surveys direct highrisk direct highrisk suppliers identified ecovadis programme work direct highrisk suppliers suppliers achieve yearly basis combination spend help improve operations support sustainability gsks minimum category highrisk countries direct journey ecovadis score procurement involves purchasing ecovadis external ratings provider assesses organisations across improvement materials directly associated four themes environment community labour human rights ethics plan place production goods sustainable procurement total number direct supplier may improvement plan place suppliers highrisk managed assessment progress supplier committed participate gsks ecovadis programme programme hasnt commenced yet supplier hasnt accepted improvement plan place defined improvement plan improvement plan implemented ongoing improvement plan supplier awaits reassessment reflect improved score reported supplier improvement plan place gsk requires suppliers minimum improvement plan initiated supplier partners ecovadis score including gsk tracked ecovadis platform required gsk interacts directly supplier ensure corrective actions implemented ecovadis scorecard data exported ecovadis platform direct highrisk suppliers identified yearly basis combination spend category highrisk countries direct procurement involves urchasing material directly associated production goods suppliers reaching minimum score given year considered met minimum entire threeyear grace period even desired minimum score increases period product governance total regulatory number regulatory inspections gsk data represents good manufacturing practice gmpgood inspections entities health authorities distribution practice gdp inspections results confirmed health authorities inspections percentage number regulatory percentage across gmp gdp results confirmed regulators inspections gsk entities critical percentage calculate total number inspections critical findings findings official action regulators critical findings official action indicated divided official action total number inspections regulators multiplied indicated total regulatory number regulatory inspections number regulatory inspections across gmpgdp based fda inspections fda following regulators gsk entities united mhra european regulators inspecting behalf ema mhraema states us federal drugs agency fda results confirmed regulators united kingdom uk medicines healthcare national competent authorities regulatory agency mhra european medicines agency ema national competent authority eea number critical number critical major findings number critical major findings across gmpgdp major findings per regulatory inspections gsk entities business products based fda mhra european regulators inspection fda us fda uk mhra ema regulators inspecting behalf ema results confirmed mhraema regulators total fda regulatory total number regulatory inspections number regulatory inspections across gmp gdp business inspections gsk entities us fda products based us fda regulatory inspections results confirmed number fda number observations issued number observations across gmpgdp business observations us fda gsk entities products based us fda regulatory inspections results confirmed number fda number warning letters issued number enforceable gmpgdp warning letters warning letters us fda gsk entities led enforced regulatory actions required gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued kpi definition method product governance total number number external class iiiiii recalls number external class iiiiii recalls across gmp gdp class iiiiii external product broken recall type product recalls class recall reasonable probability use exposure violative product cause serious adverse health consequences death class ii recall use exposure violative product may cause temporary medically reversible adverse health consequences probability serious adverse health consequences remote class iii recall use exposure violative product likely cause adverse health consequences fda product recalls number us fda recalls product business units track recall data electronic system business class us market categorise data according businesses relates pharmaceutical vaccine according recall type publicly available trial number trial protocol summaries studies protocol summaries registered gsk trial protocol summaries registered results summaries disclosed register wwwgskstudyregistercom viiv register wwwviiv register result external facing gsk trial register viiv studyregistercom numbers represent studies initiated summaries disclose register part gsks internal policy current year protocol summaries registered commitment disclosure human subject cumulative values numbers represent studies research addition mandatory protocol summaries registered gsk register requirements regulators disclosure registered viiv study register protocol registrations numbers generated transparency report derives data disclosure system used business people disclosures overall turnover overall turnover measure gsk calculate number leavers year percentage employees leaving gsk include average reporting years permanent headcount internal moves within gsk employee turnover rate includes employees left company voluntarily involuntarily year data updated daily extracted gskwide hr platform data based effective date termination termination date termination date last day work effective date termination first day termination ie following day therefore employees termination dates december reporting year included dataset reportable injury gsk reportable injury illness meets assessed reviewed ehs site team approvalclosure record illness following criteria ehs one system part reporting process ust employee gsksupervised worker must gsk workrelated ust meet one general criteria medical treatment beyond first aid b restricted daysjob transferdays away work c loss consciousness significant occupational injury occupational illness diagnosed physician licensed healthcare professional e fatality ust new case gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued kpi definition method people disclosures fatalities workrelated fatalities employees per gsk standard workrelated incidents required reported complementary workers gsk direct gsks ehs one system supervision fatalities contractors fatalities contractors gsk direct per gsk standard workrelated incidents required reported supervision related work gsk gsks ehs one system reportable injuries injuries global gsk site level meeting per gsk standard workrelated incidents required reported lost time criteria gsk reportable resulted lost gsks ehs one system time lost time includes workrelated incidents resulted lost days restricted time job transfer reportable illnesses number illnesses global gsk site level per gsk standard workrelated incidents required reported lost time meeting criteria gsk reportable gsks ehs one system resulted lost time lost time includes work related incidents resulted lost days restricted time job transfer lost time reportable number reportable injuries lost reportable lost time injuries divided total hours worked injury rate per days restricted work job transfers rated per gsk employeesgsk supervised workers hours hours worked worked lost time reportable number reportable illnesses lost reportable lost time illnesses divided total hours worked illness rate per days restricted work job transfers rated per gsk employeesgsk supervised workers hours hours worked worked reportable injuries total number injuries meet criteria per gsk standard workrelated incidents required reported without lost reportable gsks ehs one system time reportable illnesses total number illnesses meet criteria per gsk standard workrelated incidents required reported without lost reportable gsks ehs one system time reportable injury rate number reportable injuries rated per reportable injuries divided 'total hours worked gsk per hours hours worked employeessupervised workers worked reportable illness rate number reportable illnesses rated per reportable illnesses divided 'total hours worked gsk per hours hours worked employeessupervised workers worked reportable injury number reportable injuries illnesses gsk reportable illnesses gsk reportable injuries illness rate per rated per hours worked divided 'total hours worked gsk employeessupervised workers hours worked hours worked hr system report hours worked hours worked based multiplying headcount th month per site hours ehs one system month total number employees active status specified employee type codes location site multiply number provide number hours location site gsk esg performance report march independent limited assurance report directors gsk plc dnv business assurance services uk limited dnv us commissioned gsk services unlimited provide limited assurance gsk plc gsk selected information presented esg performance report report reporting year ended december conclusion basis work undertaken nothing came attention suggest selected information fairly stated prepared material respects accordance criteria conclusion relates selected information read context independent limited assurance report particular inherent limitations explained overleaf observations areas improvement raised separate report gsks management observations affect conclusion set selectedinformation scope boundary work restricted metrics included within report current reporting year selected information listed appendix environmental social governance esg performance data listed appendix document overall esg performance rating score track relating gsks performance performance rating metrics listed pages report assess selected information includes assessment risk material misstatement report used gsks esg data collection process controls documents summarised esg reporting criteria criteria found pages report performed work express conclusion information may published report gsks website current reporting period previous periods standard level assurance competence independence performed limited assurance engagement specified data information using dnvs assurance methodology verisustaintm based professional quality control experience international assurance best practice including international standard assurance engagements isae assurance engagements dnv established policies procedures audits reviews historical financial information revised issued designed ensure dnv personnel applicable others subject international auditing assurance standards board methodology ensures independence requirements including compliance ethical requirements mandates planning execution personnel entities dnv assurance engagement obtain limited level assurance maintain independence required relevant ethical requirements dnv applies management standards compliance policies quality control engagement work carried based principles enclosed within iso iec conformity independent team sustainability assessment general principles requirements validation verification bodies assurance professionals dnv provide services gsk accordingly maintains comprehensive system quality control including could compromise independence documented policies procedures regarding compliance ethical requirements impartiality work multi professional standards applicable legal regulatory requirements disciplinary team consisted professionals combination environmental procedures performed limited assurance engagement vary nature sustainability assurance experience shorter extent reasonable assurance engagement consequently level assurance obtained limited assurance engagement substantially lower assurance would obtained reasonable assurance engagement performed gsk esg performance report march basis conclusion inherent limitations required plan perform work order consider risk material dnvs assurance engagements based misstatement selected information work included restricted assumption data information provided gsk us part conducting interviews gsks management obtain understanding key review provided good processes systems controls place generate aggregate report faith true complete sufficient selected information authentic free material misstatements selected remote site visits evreux france ste foy canada stevenage uk review nature sampling inherent processes systems preparing site level health safety data limitations procedures systems consolidated company level dnv free choose sites based materiality internal control remains unavoidable risk errors irregularities performing limited substantive testing selective basis selected information possibly significant may check data appropriately measured recorded collated detected engagement excludes sustainability management performance reported reporting practices companys reviewing evidence measurements scope provided us gsk suppliers contractors third parties mentioned report understand selected information prepared line criteria reported financial data governance assessing appropriateness criteria selected information related information based statutory disclosures audited financial reading report narrative accompanying selected information within statements subject separate regard criteria independent statutory audit process review financial disclosures data assurance process come across limitations scope within scope agreed assurance engagement assurance engagement disclaimers responsibilities directors assurance provided dnv limited selected indicators information gsk dnv specified scope engagement dnv conducted assessment reporting organisation 's overall adherence reporting principles preparation directors gsk sole responsibility report therefore conclusions drawn regarding reporting organization 's compliance reporting principles quality overall report preparing presenting selected assurance provided dnv based selected indicators information information accordance made available us time engagement dnv assumes responsibility criteria changes updates made indicators information completion designing implementing assurance engagement maintaining effective internal controls information data resulting use distribution independent limited assurance report preparation selected information free material misstatements report intended solely information use directors gsk intended used anyone specified parties measuring reporting selected dnv expressly disclaims liability coresponsibility decision person information based established criteria entity may make based independent limited assurance report contents statements contained within report criteria dnv business assurance services uk limited responsibility plan perform work obtain limited assurance london uk whether selected information march prepared accordance criteria report gsk form independent limited assurance conclusion wallis digitally signed waldendigitally signed based work performed c ho op llyley b c p w el e h zo l ly shaun w aa l ed e n zh u n e r rev esi pd p oe rn n tc e ib leb foai rn te hd e pw ree p h aa rv ae ti b f e en holly walliscopley shaun walden lead verifier technical reviewer dnv supply chain product dnv business assurance services uk dnv business assurance services uk assurance limited limited dnv business assurance services uk limited part dnv supply chain product assurance global provider certification verification assessment training services enabling customers stakeholders make critical decisions confidence wwwdnvcoukbetterassurance dnvasrc gsk esg performance report march appendix selectedinformation scope boundary work restricted selected information including esg performance data listed continued overleaf esg performance data reported value unit access cash product inkind time management costs total community investment value gsk medicine vaccines provided us patient assistance programs foundation doses synflorixvaccines supplied gavi doses rotarixvaccines supplied gavi doses cervarixvaccines supplied gavi doses opv vaccines supplied unicef doses opv vaccines supplied readytoship stockpile unicef doses mosquirix rtssas e vaccines supplied albendazole tablets donated help eliminate lymphatic filariasis albendazole tablets donated help treat intestinal worms total doses supplied people access generic dolutegravir product voluntary licensing agreements estimated children reached synflorixthrough gavi estimated children reached rotarixthrough gavi estimated girls reached cervarixthrough gavi estimated people reached opv unicef estimated people reached mosquirix rtssas e total people reached people reached us patient assistance programs global health health security number assets progressed global health pipeline address priority diseases environment percentage carbon offset volume project pipeline percentage mtcooffsetting volume project pipeline diversity equity inclusion percentage phase iii trials initiated proactive plans place designed enrol appropriately diverse trial participants consistent disease epidemiology us ethnic diversity ethnically diverse total svpvp director manager employees uk ethnic diversity ethnically diverse total svpvp director manager employees women employees svpvp director manager total women management ethical standards employees concerns raised including current year prior year open cases employees disciplined policy violations gsk esg performance report march appendix selectedinformation continued esg performance data reported value unit breakdown types policy violation employee conduct sales marketing product quality safeguarding people information assets employee relations research development medical practices antibribery corruption cyber security ehs sustainability employees dismissed agreed leave company voluntarily result ofmisconduct documented warnings open cases awaiting investigation disciplinary decision year end employees complementary workers complete gsks mandatory training employees believe speak things n't feel right direct highrisk suppliers achieve gsks minimum ecovadis score improvement plan place product governance total regulatory inspections health authorities inspections regulators critical findings official action indicated total regulatory inspections fdamhraema regulators number criticalmajor findings fdamhraema regulators total fda regulatory inspections number fda observations number fda warning letters total product recalls total number class external product recalls total number class ii external product recalls total number class iii external product recalls pharmaceuticals business class product recalls pharmaceuticals business class product ii recalls pharmaceuticals business class product iii recalls vaccines business class product recalls vaccines business class product ii recalls vaccines business class product iii recalls publicly available trial protocol summaries register publicly available trial result summaries disclose people disclosures overall turnover number fatalities employees complementary workers gsk direct supervision fatalities contractors gsk direct supervision reportable injuries lost time reportable illnesses lost time lost time reportable injury rate per hours worked lost time reportable illness rate per hours worked reportable injuries without lost time reportable illnesses without lost time reportable injury rate per hours worked reportable illness rate per hours worked reportable injury illness rate per hours worked hours worked gsk esg performance report march iinnddeeppeennddeenntt lliimmiitteedd aassssuurraannccee rreeppoorrtt ttoo tthhee ddiirreeccttoorrss ooff ggsskk ppllcc independent limited assurance report deloitte llp directors gsk plc selected environmental social governance esg metrics selected information within annual report accounts esg performance report reporting year ended december oouurr aassssuurraannccee ccoonncclluussiioonn based procedures described report evidence obtained nothing come attention causes us believe selected information presented annual report accounts pages esg performance report year ended december listed indicated annual report accounts esg performance report prepared material respects accordance basis reporting defined directors ssccooppee ooff oouurr wwoorrkk gsk plc engaged us perform independent limited assurance engagement accordance international standard assurance engagements revised assurance engagements audits reviews historical financial information isae revised international standard assurance engagements assurance engagements greenhouse gas statements isae issued international auditing assurance standards board iaasb agreed terms engagement selected information scope engagement presented annual report accounts pages esg performance report year ended december listed indicated annual report accounts esg performance report follows sseelleecctteedd iinnffoorrmmaattiioonn aassssuurreedd vvaalluuee scope emissions thousand tonnes coe scope emissions market based thousand tonnes coe scope emissions location based thousand tonnes coe total scope marketbased emissions thousand tonnes coe total energy operations gwh purchased renewable electricity gwh onsite renewably generated electricity gwh emissions use propellant based inhalers patients thousand tonnes coe total water use high water risk sites million total wastewater discharged million total water use million basis reporting defined gsk plc nature selected information absence consistent external standards allow different acceptable measurement methodologies adopted may result variances entities adopted measurement methodologies may also impact comparability selected information reported different organisations year year within organisation methodologies develop selected information listed table needs read understood together basis reporting prepared published gsk plc esg resources gsk iinnhheerreenntt lliimmiittaattiioonnss ooff tthhee sseelleecctteedd iinnffoorrmmaattiioonn obtained limited assurance preparation selected information accordance applicable criteria inherent limitations exist assurance engagements internal control structure matter effective eliminate possibility fraud errors irregularities may occur remain undetected use selective testing engagement guarantee errors irregularities present detected selfdefined basis reporting nature selected information absence consistent external standards allow different acceptable measurement methodologies adopted may result variances entities adopted measurement methodologies may also impact comparability selected information reported different organisations year year within organisation methodologies develop inherent limitations exist assurance engagements due selective enquiry information examined therefore fraud error noncompliance may occur detected work involve testing operating effectiveness controls underlying data sought review systems controls beyond relevant selected esg metrics ddiirreeccttoorrss rreessppoonnssiibbiilliittiieess directors responsible preparing annual report accounts complies requirements companies act satisfied annual report accounts esg performance report taken whole fair balanced understandable directors also responsible selecting establishing basis reporting preparing measuring presenting reporting selected information accordance basis reporting publishing basis reporting publicly advance time publication selected information designing implementing maintaining internal processes controls information relevant preparation selected information ensure free material misstatement including whether due fraud error providing sufficient access making available necessary records correspondence information explanations allow successful completion services confirming us written representations provided us information relevant services aware measurement evaluation underlying subject matter basis reporting including relevant matters reflected selected information gsk esg performance report march oouurr rreessppoonnssiibbiilliittiieess responsible planning performing procedures obtain sufficient appropriate evidence order express independent limited assurance conclusion selected information communicating matters may relevant selected information appropriate party including identified suspected noncompliance laws regulations fraud suspected fraud bias preparation selected information reporting conclusion form independent limited assurance report directors oouurr iinnddeeppeennddeennccee aanndd ccoommppeetteennccee conducting engagement complied independence requirements frcs ethical standard icaew code ethics icaew code founded fundamental principles integrity objectivity professional competence due care confidentiality professional behaviour applied international standard quality management isqm issued international auditing assurance standards board accordingly maintained comprehensive system quality management including documented policies procedures regarding compliance ethical requirements professional standards applicable legal regulatory requirements kkeeyy pprroocceedduurreess ppeerrffoorrmmeedd required plan perform work address areas identified material misstatement respect selected information likely arise procedures performed based professional judgment carrying limited assurance engagement respect selected information performed following procedures performed analytical review procedures considered risks material misstatement selected information inquiries management obtained understanding company environment processes information systems relevant preparation selected information sufficient identify assess risks material misstatement selected information provide basis designing performing procedures respond assessed risks obtain limited assurance support conclusion inquiries management obtained understanding internal controls relevant selected information quantification process data used preparing selected information methodology gathering qualitative information process preparing reporting selected information evaluate design particular internal control activities obtain evidence implementation test operating effectiveness inspected documents relating selected information including sustainability council minutes applicable internal audit outputs understand level management awareness oversight selected information performed procedures selected information including recalculation relevant formulae used manual calculations assessment whether data appropriately consolidated performed procedures underlying data statistical sample basis assess whether data collected reported accordance basis reporting including verifying source documentation conducted site visits sample sites selected judgemental basis determine consistency understanding application basis reporting gsk esg performance report march performed procedures selected information including assessing managements assumptions estimates applicable accumulated misstatements control deficiencies identified assessing whether material read narrative accompanying selected information regard basis reporting consistency findings procedures performed limited assurance engagement vary nature timing less extent reasonable assurance engagement consequently level assurance obtained limited assurance engagement substantially lower assurance would obtained reasonable assurance engagement performed uussee ooff oouurr rreeppoorrtt report made solely directors gsk plc accordance isae revised isae agreed terms engagement work undertaken might state directors gsk plc matters agreed state report purpose without assuming accepting responsibility liability respect report party gsk plc directors gsk plc acknowledge directors gsk plc may choose make report publicly available others wishing access affect extend purpose basis responsibilities fullest extent permitted law accept assume responsibility anyone gsk plc directors gsk plc body work report conclusions formed ddeellooiittttee llllpp london uk february gsk esg performance report march